Podcasts about geisel school

The greatest obstacle to productivity isn't a lack of time, skill, or effort—it's the invisible weight of doubt, stress, and worry. We grind ourselves down, convinced that success comes from doing more, when in reality, true effectiveness begins with thinking better. In this episode of the Productivity Smarts Podcast, Gerald J. Leonard sits down with retired pediatrician Dr. Ron Schneebaum to uncover a truth that could transform the way you approach work, relationships, and life. Together, they explore the powerful connection between emotional health, happiness, and productivity. Dr. Schneebaum shares his transformative journey in medicine, where he adopted a holistic approach to patient care—treating the whole person, not just their symptoms. He reveals how compassion, love, and empathy are essential for not only healing but managing stress and thriving in all aspects of life. The conversation delves deeper into childhood trauma's lasting effects and the importance of addressing emotional wounds for personal growth. One of the episode's most impactful moments is Ron's morning reflection routine, a practice that grounds him and helps him face challenges with calm and purpose. If you're ready to shift your mindset and live with more intention, this episode is a must-listen. Tune in to learn how nurturing your emotional health can unlock your full potential—both at work and in life. What We Discuss [02:02] - Introduction to Dr. Ron Schneebaum [08:03] - Learning effective study techniques [11:06] - Building personal connections in medicine [14:49] - Lessons learned from illness [17:14] - Introduction to Ron's book [19:05] - The impact of COVID-19 on work life [21:55] - Managing stress in the medical field [23:10] - Morning visualization techniques [25:04] - Reviewing daily interactions for growth [28:25] - The magic of consistent practice [32:26] - Healing childhood wounds and making progress [39:25] - The influence of role models in adolescence [43:45] - Conclusion and additional resources   Notable Quotes [07:48] "When I saw medicine as a possibility of it being intellectually challenging and having this interpersonal side, I said that's what I wanted to do." — Ron    [20:00] "At the end of the day, no one ever sits on their deathbed and talks about the hours they spent in the office. They talk about the loved ones they spent time with, the people they helped, the memories they created, the things that they did that made a difference in other people's lives." — Gerald J. Leonard   [21:18] "When you care more about the person than just about getting the job done, the job will get done, but the person will be engaged." — Ron    [23:10] "One of the ways that I find is a great stress reliever, and this is available for everyone, is to set your alarm clock for about 10 or 15 minutes earlier than you need to get up and visualize your day ahead." — Ron    [29:05] "Think of somebody in jazz, like the greats doing their solos, or Ella Fitzgerald doing her scat stuff where she ends up back where she started. It didn't come out of her never having practiced it; she really worked at it." — Ron    Our Guest Dr. Ron Schneebaum is a retired pediatrician with over 40 years of experience in the medical field. A Diplomate of the American Board of Pediatrics and a fellow of the American Academy of Pediatrics, he served on the clinical faculty of Dartmouth College's Geisel School of Medicine. There, he founded the "Fresh Perspectives" program to support children and teens with behavioral, emotional, psychological, and academic challenges. Renowned for his teaching, Dr. Schneebaum was voted Best Teacher in Pediatrics by Dartmouth medical students. After retiring from clinical practice, he shifted his focus to helping individuals live happier, more fulfilled lives. Through his book, Bigger Hearted, and his podcast, On Being Happier: Thinking with Heart and Mind, he shares valuable insights on emotional well-being and personal growth. Outside of his professional work, Dr. Schneebaum enjoys organic gardening, hiking, woodworking, photography, and cooking, while continuing to advocate for mental and emotional well-being.   Ron Schneebaum Website https://ronschneebaummd.com/ LinkedIn: https://www.linkedin.com/in/ron-schneebaum-b1515321 Book: https://www.amazon.com/Bigger-Hearted-Retired-Pediatricians-Prescriptions-ebook/dp/B0DQJYPW3Y   Productivity Smarts Podcast Website - productivitysmartspodcast.com   Gerald J. Leonard Website - geraldjleonard.com Turnberry Premiere website - turnberrypremiere.com Scheduler - vcita.com/v/geraldjleonard Kiva is a loan, not a donation, allowing you to cycle your money and create a personal impact worldwide. https://www.kiva.org/lender/topmindshelpingtopminds  

In today's episode, I had the pleasure of speaking with Dr. John Randolph - a board-certified clinical neuropsychologist, brain health consultant, and Clinical Assistant Professor of Psychiatry at Dartmouth's Geisel School of Medicine. He's the past president of both the National Academy of Neuropsychology and the New Hampshire Psychological Association, and his research focuses on cognitive health, executive functioning, and resilience. He's also the author of The Brain Health Book: Using the Power of Neuroscience to Improve Your Life.In our conversation, Dr. Randolph breaks down the CAPE model—a simple and powerful way to think about and take care of our brain health. We talked about cognitive strategies, activity engagement, preventing cognitive problems, and education about our brains. And, how small, consistent actions can make a big difference in our long-term brain health. We also discuss the impact of sleep, exercise, and social connections, which was validating for me as this is what I always like to ask my clients about. Dr. Randolph also shares a little about the research he's doing with people with multiple sclerosis to figure out how to improve cognitive resilience. Our brains are fascinating, so listen today to learn how we can extend and enrich our lives by taking care of them!Show NotesLearn More About Dr. John Randolphhttps://www.randolphnp.com/about-dr-john-randolphThe Brain Health Book: Using the Power of Neuroscience to Improve Your Lifehttps://wwnorton.com/books/978039371287212 ways to keep your brain younghttps://www.health.harvard.edu/mind-and-mood/12-ways-to-keep-your-brain-youngBuild Better Work Habits: How Your Brain Changes with Practicehttps://www.beyondbooksmart.com/executive-functioning-strategies-blog/build-better-work-habits-how-your-brain-changes-with-practiceThe Quiz My Colleague Used With Her Clienthttps://www.viacharacter.org/account/registerLearn More About 1:1 Coachinghttps://www.beyondbooksmart.com/how-it-worksLearn More about BrainTracks Teacher Professional Developmentwww.braintracks.comGet in Touchpodcast@beyondbooksmart.comInstagram/Facebook/Tiktok: @beyondbooksmartcoachingwww.beyondbooksmart.com

You're invited to ask an expert about interesting topics related to employment. This free event is not a presentation, but rather an interactive question & answer webinar. And YOU provide the questions! Kim T. Mueser, Ph.D. is Professor of Occupational Therapy and Psychological and Brain Sciences, researcher at the Center for Psychiatric Rehabilitation at Boston University, and Adjunct Professor of Psychiatry at the Geisel School of Medicine at Dartmouth. His research interests are on the development and evaluation of psychosocial interventions for persons with serious mental illnesses. His most recent book is: Mueser, K. T., Bellack, A. S., Gingerich, S., Agresta, J., & Fulford, D. (2024). Social Skills Training for Schizophrenia: A Step-by-Step Guide (Third ed.). Guilford Press.

In episode 179 of the Thyroid Answers Podcast, I discuss thyroid cancer with Louise Davies, MD.  Topics covered in this episode include: The types of thyroid cancer. Is thyroid cancer on the rise? Thyroid nodules identified and the next steps. Why suppressing TSH with T4 medication is a strategy to prevent thyroid cancer from returning. Could inappropriate use of thyroid medication be harmful? Typical treatment strategies for thyroid cancer. And more... Louise Davies is Professor of Surgery - Otolaryngology – Head and Neck Surgery at the Geisel School of Medicine at Dartmouth, and of The Dartmouth Institute for Health Policy and Clinical Practice. Her clinical practice focus is thyroid and parathyroid disease and cancers of the head and neck.   She is best known for her work defining the problem of overdiagnosis in thyroid cancer. In recent years, she has focused on mitigating the harm that can come from overdiagnosis, working to develop evidence that can inform patient and physician decision-making. Her research has also focused on population health issues, including making recommendations for thyroid monitoring after nuclear accidents and the recovery of the healthcare system after the pandemic .

In this special episode, RAPM Focus takes a break from its usual format of discussing specific research projects to discuss instead how research in health care is increasingly vital yet often hindered by escalating costs and time constraints. Editor-in-Chief Brian Sites, MD, discusses these challenges with Alexander (Xan) Abess, MD, and Jonathan Weed, MD. Traditional, large scale, randomized controlled trials are resource intensive, making them challenging for clinicians to conduct. As a result, innovative approaches to engage in knowledge acquisition are becoming paramount. Creating a scholastic environment within the anesthesia department not only fosters a culture of continuous learning, but also becomes essential for attracting and retaining talent. Dr. Abess is an anesthesiologist at Dartmouth Hitchcock Medical Center and assistant professor of anesthesiology and perioperative medicine at Geisel School of Medicine at Dartmouth. He has previously served as the vice chair of quality and safety, department of anesthesiology and perioperative medicine, and is actively involved with the Multi-Center Perioperative Outcomes Group (MPOG). He is the founder and Director of IDEA Lab (Innovation, Development, and Entrepreneurship in Anesthesiology). Xan has a wide range of clinical experience (private practice, academic medicine, military medicine) and medical device development experience, having previously started his own medical device company. He understands well the challenges of medical innovation and truly enjoys helping others achieve their development goals while also attempting to improve the quality of health care delivery and simultaneously addressing our broader economic and workforce challenges. Dr. Weed is a clinical assistant professor of anesthesiology at Dartmouth Hitchcock Medical Center. He is a graduate of Tulane Medical School and completed his anesthesiology residency at Beth Israel Deaconess Medical Center, followed by a fellowship at Dartmouth Hitchcock Medical Center in regional anesthesia. He spent several years as a residency program director at Tulane Medical Center before returning to Tulane Medical Center in 2021. His most recent interests relate to the use of the electronic health record to improve clinical workflow in research within the department. *The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice, and it is not intended to function as a substitute for a health care practitioner's judgment, patient care, or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others. Podcast and music produced by Dan Langa. Find us on X @RAPMOnline, Facebook @Regional Anesthesia & Pain Medicine, and Instagram @RAPM_Online.

BUFFALO, NY- August 14, 2024 – A new #editorial was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 14 on July 17, 2024, entitled, “Recalibrate concepts of epigenetic aging clocks in human health.” As detailed in the opening of this editorial, DNA methylation-based epigenetic clocks are used as biomarkers of biological age in human health. Multiple epigenetic clocks have rapidly emerged in the past decade by modeling DNA methylation changes with age in large cohorts, primarily using peripheral blood samples. Despite efforts to understand the functional implications of features used to estimate biological age, the underlying mechanisms of these clocks remain poorly understood, leading to potential misinterpretations of their associations with health outcomes. Researchers Ze Zhang, Brock C. Christensen, and Lucas A. Salas from the Divisions of Population Sciences and Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, the Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center, and the Department of Molecular and Systems Biology, Geisel School of Medicine, Dartmouth College explored the association of 12 immune cell types with epigenetic age acceleration (EAA) in both healthy and diseased populations. Their work sheds light on the complex interplay between immune cell composition and epigenetic aging, utilizing high-resolution methylation cytometry in blood samples. “In this editorial, we aim to address the key implications of our study on epigenetic aging clocks in human health from a broader perspective. While epigenetic clocks are widely hyped as aging biomarkers today, it's essential to recalibrate some fundamental concepts in this field.” DOI - https://doi.org/10.18632/aging.206027 Corresponding author - Lucas A. Salas - lucas.a.salas@dartmouth.edu Video short - https://www.youtube.com/watch?v=9lV-pkYm22M Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206027 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, epigenetics, DNA methylation, epigenetic clock, epigenetic age acceleration, methylation cytometry About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

In 2020 and 2021, a secret Pentagon program deployed fake social media accounts to sow distrust among people in Southeast Asian countries, particularly the Philippines, around China's Sinovac vaccination for COVID-19. Clusters of accounts identified as having ties to US Central Command (CENTCOM) made posts with the hashtag #ChinaAngVirus - or “China is the virus” in Tagalog suggested that the coronavirus is real, but China's vaccinations were not to be trusted. Posts in Arabic and Russian also targeted audiences in the Middle East and Central Asia.In an article published on June 14 by Reuters, an infectious disease specialist at Dartmouth's Geisel School of Medicine said of the propaganda campaign, “I don't think it's defensible.”Dr. Nina Castillo-Carandang, a former adviser to the World Health Organization and Philippines government said “Why did you do it when people were dying? We were desperate”We're joined by Chris Bing, an investigative reporter with Reuters who worked on the June 14th article.Read the full article here: https://www.reuters.com/investigates/special-report/usa-covid-propaganda/Read the Stanford Internet Observatory's “Unheard Voice” report mentioned in our conversation: https://cyber.fsi.stanford.edu/io/news/sio-aug-22-takedownsSupport the Show.

In this episode, host Dr. Erkeda DeRouen chats with Dr. Chiamaka Okorie, a recent graduate of Geisel School of Medicine at Dartmouth. Dr. Okorie brings a unique perspective as an international student who excelled in the US system, acing the MCAT and building an impressive portfolio. Dr. Okorie shares practical advice for aspiring dermatologists, but her insights extend far beyond a single specialty. Tune in to learn about exploring career paths early, the power of networking, and the importance of self-advocacy. They'll delve into crafting a standout application, the value of passion-driven research, and the importance of building your support system. In this episode, you'll learn: Depths of Dermatology: Dr. Chiamaka Okorie advises aspiring dermatologists to jump into the field early and seek guidance from professionals to build a competitive portfolio Self-Advocacy is Key: Both Dr. Chiamaka Okorie and our host, Dr. Erkeda DeRouen, emphasize the importance of actively showcasing your achievements and interests. Building Your Personal Board of Directors: Proactively reaching out to professionals and leveraging digital platforms can provide invaluable guidance and support in your medical journey, from medical school decisions to career development. Jump into the Conversation: [00:00] Introduction to the Prospective Doctor [02:01] Introduction to Dr. Chiamaka Okorie [02:43] Navigating getting into a US medical school for international students [04:16] - Tips for building a competitive portfolio early on, including the power of mentorship and networking [10:36] Dr. Okorie's advice on fully committing to the desired specialty, including advocacy tips and strategies for standing out [15:14] The importance of research in building your portfolio [19:44] Building your network on LinkedIn, Instagram and other social media platforms [21:00] The competitive specialty of dermatology [28:37] Advocating for yourself in medical school   Where you can find Dr. Okorie:  Email: chiamakaokoriemd@gmail.com  Twitter: @AmakaOkorieMed LinkedIn: https://www.linkedin.com/in/chiamakaokorie/   To learn more about how MedSchoolCoach can help you along your medical school journey, visit us at www.prospectivedoctor.com/   You can also reach us through our social media: Facebook: https://www.facebook.com/MedSchoolCoach  Dr. Erkeda's Instagram: https://www.instagram.com/doctordgram/  YouTube: www.youtube.com/@MedSchoolCoach  

Today's disagreement is on medical aid in dying. In the United States, this term refers to the right for a terminally ill, adult patient to end their own life by taking a medication prescribed by a doctor. Medical aid in dying is currently legal in ten states and Washington, D.C.We've brought together an activist and a doctor to dive into the topic:Dr. Ira Byock is a physician, author, and advocate for palliative care — the medical practice of treating people with serious, complex, and terminal illnesses. Ira is the founder of the Providence St. Joseph Health Institute for Human Caring and is an emeritus professor of medicine and professor of community health and family medicine at the Geisel School of Medicine at Dartmouth College.Kim Callinan is an end-of-life leader and advocate in the field of medical aid in dying. She is President and Chief Executive Officer of Compassion & Choices, an organization that aims to “improve care, expand options and empower everyone to chart their end-of-life journey.”Today we ask a wide range of important questions on medical aid in dying.How broken is end-of-life care in America? And how should we fix it?What are the potential risks and benefits of implementing medical aid in dying?How should we be thinking about death, dying, and the end-of-life for our loved ones?And one more very exciting note: today's disagreement is facilitated by Catherine Cushenberry, one of our producers and someone who has been helping to bring the idea for this podcast to life from the very beginning. Catherine is also a healthcare industry veteran and the perfect facilitator for this topic.And as you'll hear, she's awesome at it.Show NotesCurrent state of end-of-life care [03:25]Palliative care [07:45]Question of unintended consequences [12:56]Defining medical aid in dying [16:47]Effect of medical aid in dying on end-of-life care [22:36]Medical aid in dying outside the U.S. [28:02]Process of medical aid in dying [33:56]Is there a slippery slope? [37:30]Reasons why people choose medical aid in dying [43:21]Financial incentives [47:08]Steelmanning [51:05]

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: William F.C. Rigby, MD Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition that can be difficult to diagnose and treat. For instance, PMR is a diagnosis of exclusion, and it can mimic a wide variety of other conditions. And once a patient is accurately diagnosed, the standard-of-care treatment with glucocorticoids may result in toxicity for some patients. Learn more about these and other diagnostic and treatment challenges as well as other treatment options with Dr. Charles Turck and Dr. William Rigby, Professor of Medicine and of Microbiology and Immunology at the Geisel School of Medicine at Dartmouth. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All rights reserved.MAT-US-2403256 v1.0 - P Expiration Date 04/16/2025

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: William F.C. Rigby, MD Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition that can be difficult to diagnose and treat. For instance, PMR is a diagnosis of exclusion, and it can mimic a wide variety of other conditions. And once a patient is accurately diagnosed, the standard-of-care treatment with glucocorticoids may result in toxicity for some patients. Learn more about these and other diagnostic and treatment challenges as well as other treatment options with Dr. Charles Turck and Dr. William Rigby, Professor of Medicine and of Microbiology and Immunology at the Geisel School of Medicine at Dartmouth. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All rights reserved.MAT-US-2403256 v1.0 - P Expiration Date 04/16/2025

When Zed Zha came to the United States for her education, she faced barriers to medical school admission and financial aid, and to establishing a sense of belonging. Then unexpectedly, she found the feeling of “home” in rural New Hampshire. Dr. Zha joins us to share her blog post Where is Home? and to take us through her journey to her life now as a doctor in rural America, focused on underserved patients. Our guest is: Dr. Zed Zha, who is a writer and a family doctor, a feminist and a fierce patient advocate. Her current work-in-progress is a non-fiction book project on medical misogyny. Dr. Zha is a board-certified family physician. She graduated from the Geisel School of Medicine at Dartmouth, where she received the Gold Humanism Honor Society Award and the John F. Radebaugh Community Service Award. She completed her residency at the Mayo Clinic - La Crosse Family Medicine Residency, where she was the recipient of the Residency Research Award. Zed practiced full-scope primary care with obstetrics and hospital medicine in rural Washington state from 2019-2022, where she served as her organization's COVID-19 Task Force Physician Lead. Currently, she is completing her fellowship in Underserved Dermatology. Our host is: Dr. Christina Gessler, the creator of the Academic Life podcast. She holds a PhD in history, which she uses to explore what stories we tell and what happens to those we never tell. Listeners may also be interested in this playlist: Far from Home: A conversation about academic relocation Gender bias in medical school and the ER Gender bias in the study of science Applying the lessons from his working class parents to his academic life, with Dr. Jorge Juan Rodríguez Community-building and How We Show Up, with Mia Birdsong Welcome to Academic Life, the podcast for your academic journey—and beyond! Please join us again to learn from more experts inside and outside the academy, and around the world. The Academic Life podcast is currently listened to in more than 150 countries. You can help support the show's mission of democratizing education and sharing the hidden curriculum by downloading episodes, and by telling a friend—because knowledge is for everybody. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/academic-life

Special Series Focus: DRP's: Emerging DRP Leaders in Medical Education Description In this episode we delve into the dynamic world of emerging leaders engaging with five remarkable professionals who are shaping the future of Disability Resource Professionals (DRPs) in medical education. Our conversation explored the essence of leadership, the qualities that define effective leaders in disability resources, and the personal journeys that have shaped our guests into the leaders they are today. This episode is a treasure trove of wisdom, and we are excited to share three key takeaways: 1. Leadership is a Journey of Continuous Growth and Adaptability Our guests shared their personal leadership paths, emphasizing that leadership isn't a static quality but a dynamic process of learning and evolving. They highlighted the importance of adaptability, critical thinking, and effective communication as cornerstones for navigating the ever-changing landscape of disability resources in health sciences. 2. The Power of Vulnerability and Authenticity in Leadership Throughout the episode, our guests underscored the significance of vulnerability and authenticity in building trust and fostering a supportive environment. Leaders who embrace their humanity and acknowledge their mistakes create a culture of openness and learning, which is essential for team growth and resilience, especially in challenging times. 3. Mentorship and Role Modeling Shape Aspiring Leaders The stories shared by our guests revealed the profound impact of mentorship and positive role modeling on their leadership development. Whether it was through formal training programs or organic relationships, the guidance and example set by seasoned leaders played a pivotal role in shaping the next generation of DRPs. This mentorship goes beyond professional development, touching on personal growth and ethical conduct. Don't forget to subscribe, like, share, and comment with your thoughts after listening or reading!  Host Lisa Meeks: The host of the podcast and mentor to all of the guests. Guests: We were joined by a diverse group of individuals, each bringing a wealth of experience and unique perspectives to the table: Matt Sullivan from Washington University in St. Louis, with over a decade of experience in disability resources and a key role in the DRP Academy. Kara James, the Disability Access Resource Specialist at the Mayo Clinic College of Medicine and Science, who has dedicated over 20 years to disability services in higher education. Emily Langham, the director of student disability services at Eastern Virginia Medical School, who has been a facilitator for the Disability Resource Professional Academy. Ellen Kaplan, the assistant director of SDS for the Johns Hopkins School of Medicine, with a background in special education and advocacy spanning over 30 years. Bill Eidtson, the assistant dean for academic advising at the Geisel School of Medicine at Dartmouth College, who has a rich history in faculty development and academic advising. Transcript Keywords: Disability Resource Professional, Disability, DRP, Accommodation, Leadership, Mentorship. Produced by: Lisa Meeks and Jacob Feeman Audio editor: Jacob Feeman Digital Media: Lisa Meeks

Show Summary In this episode of Admission Straight Talk, host Linda Abraham addresses the concerns of medical school applicants who have not yet received interview invitations. She debunks the myth that not receiving an invitation by Thanksgiving means rejection and shares insights from several admissions directors. She offers tips for both current med school applicants and those preparing for a reapplication.  Show Notes Welcome to the 555th episode of Admissions Straight Talk. Thanks for tuning in. This episode is for those of you who applied this cycle to medical school and haven't received any interview invitations or at least haven't received an interview invitation from your top choice schools. We're also going to discuss a little bit about what you should be doing now –  neither hitting a panic button nor just worrying and chewing your nails – which is preparing for the possibility of a reapplication. Before we dive in, I have two free resources that I'd like to invite you to take advantage of: The Ultimate Guide to Medical School Interview Success and Medical School Applicant Advice: 6 Tips For Success.  Welcome to Admissions Straight Talk. [1:00] If you are a regular listener, you know that during most episodes of Admissions Straight Talk, I interview a guest. Occasionally I give a solo show, but usually I interview a guest and frequently that guest is an admissions directors. I also have many times asked guests who are med school admissions deans or directors, “When do you stop sending out interview invitations?” I started asking this question because many applicants believed incorrectly that if they don't have an interview invitation by Thanksgiving, they are toast. And here we are in the midst of the Christmas and New Year holidays, and if you haven't gotten the invitation by now, are you actually burnt toast? Well, let's hear what five admissions deans and directors have said in response to my question.  The five are:  Roshini Pinto-Powell, the Associate Dean for Admissions at Dartmouth Geisel School of Medicine Paul White, Assistant Dean for Admissions at Johns Hopkins School of Medicine Dr. Kristen Goodell, Associate Dean of Admissions at BU's Chobanian and Avedisian School of Medicine Dr. Michael Ellison, Associate Dean for Admissions at Chicago Medical School at the Rosalind Franklin University Dr. Cynthia Boyd, Associate Dean for Admissions and Recruitment at Rush Medical College Today's episode is a collection of their answers to that question,  “When do you stop sending out interview invitations?” At the end there's a  little commentary from me, but mostly it's admissions directors and their own words. These are admissions directors at top medical programs sharing what you need to know about the interview invitation timeline.  Dr. Roshini Pinto-Powell, Professor of Medicine and Medical Education and Associate Dean of Admissions at the Geisel School of Medicine at Dartmouth University. [4:20] [RPP] So, our process is a rolling process. We do rolling admissions and we continue to send out invitations well into March. And similarly with the waitlist, that's another thing that people worry about. This is a long process, which is why I said I feel sorry for our candidates. It's a long year. It's a long year. Paul White, Assistant Dean for Admissions at Johns Hopkins School of Medicine. [5:09] [PW] Well, when it was in person, the last date would be around the first week of February. With virtual interviews, we literally sometimes invite people three or four days before the interview. I would say at least a week before is ideal. Mid-February to late February, certainly not the day before. Yeah, we want to give a heads-up, but when it was in person because of travel in February, we always did minimally two weeks in advance. The reason I asked this question is because there's this meme out there that if you don't have an interview invitation by T...

On November 2, 2023 we spoke with Allan Gulledge on the function of neuromodulation and neuromodulators, especially acetylcholine, in the cerebral cortex. We asked him about their role is cortical signal processing and state changes in the circuit. Guest: Allan Gulledge, Professor of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth College Participating: David Jaffe, Department of Neuroscience, Developmental and Regenerative Biology, UTSA Host: Charles Wilson, Department of Neuroscience, Developmental and Regenerative Biology, UTSA Thanks to James Tepper for original music.

Jamie Hartmann-Boyce and Nicola Lindson discuss emerging evidence in e-cigarette research and interview Associate Sarah Pratt, Department of Psychiatry, Geisel School of Medicine, Dartmouth University, New Hampshire, USA. Associate Professor Jamie Hartmann-Boyce and Dr Nicola Lindson discuss the new evidence in e-cigarette research and interview Associate Professor Sarah Pratt from Dartmouth University. This podcast is a companion to the electronic cigarettes Cochrane living systematic review and shares the evidence from the monthly searches. Sarah Pratt discusses her research and her study of e-cigarette provision to people with serious mental illness to support them transitioning away from combustible tobacco. This research is funded by the US National Institute on Drug Abuse. An abstract of this work was presented at the Society for Research into Nicotine and Tobacco, SRNT, meeting in 2023 and published in Nicotine & Tobacco Research last year. People with serious mental illness (SMI) have great difficulty quitting and sustaining abstinence, warranting novel harm reduction strategies, including switching to potentially reduced-harm nicotine products, such as e-cigarettes. Sarah Pratt and her team conducted the first-ever trial of e-cigarette provision with instructions on their safe use versus usual care in 240 chronic smokers with SMI. They tested whether substitution of e-cigarettes could reduce harm as measured by the cigarette metabolite and carcinogen NNAL (the nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol). The e-cigarette group had significantly lower NNAL at 4 weeks but the group difference was attenuated at 8 weeks. This study demonstrated rapid short-term harm reduction among chronic smokers with SMI assigned to receive e-cigarettes. The attenuation of this effect at 8 weeks suggests that smokers with SMI require more than e-cigarette provision alone to maintain reduced smoking. Sarah and her team conclude that development of a behavioural intervention in addition to e-cigarette provision seems warranted to prevent morbidity and early mortality in this high-risk group of smokers. For more information on the study see: Pratt SI, Ferron JC, Brunette MF, Santos M, Sargent J, Xie H. E-Cigarette Provision to Promote Switching in Cigarette Smokers with Serious Mental Illness-A Randomized Trial. Nicotine Tob Res. 2022 Aug 6;24(9):1405-1412. doi: 10.1093/ntr/ntac082. PMID: 35363874; PMCID: PMC9356685. SRNT 2023, abstract PPS22-5, RCT assessing the effect of e-cigarettes versus usual smoking on NNAL among chronic smokers with serious mental illness.

In this episode, Professor of Medicine and Medical Education and Associate Dean of Admissions at the Geisel School of Medicine at Dartmouth University explains the draw of the close-knit community at Dartmouth, why the school doesn't send secondaries to applicants with an MCAT below 503, and how to ace Geisel's secondary.  [SHOW SUMMARY] Are you dreaming of becoming a doctor at an Ivy league medical school, one of the best in the country? Do you want to learn how to ace the admissions process at Dartmouth Geisel School of Medicine? Tune in to this episode of Admissions Straight Talk, where I interview Dr. Roshini Pinto-Powell, the Associate Dean for Admissions at Geisel, and get her insider tips on what makes a successful applicant. An interview with Dr. Roshini Pinto-Powell, Associate Dean of Admissions at Geisel and Professor of Medicine. [Show Notes] Welcome to the 530th episode of Admissions Straight Talk. Thanks for joining me today. Are you ready to apply to a dream medical school? Are you competitive at your target programs? Accepted's  Med School Admissions quiz can give you a quick reality check. Complete the quiz, and you'll not only get an assessment, but tips on how to improve your qualifications and your chances of acceptance. Plus, it's all free.  Our guest today is Dr. Roshini Pinto-Powell. Dr. Pinto-Powell grew up and earned her bachelor's degree in chemistry in India. She earned her MD at the Ross School of Medicine. She did two fellowships in infectious disease and returned with her husband to Dartmouth where she actually focused on general internal medicine. She also found that she loved teaching, and today is a professor of medicine and a professor of medical education as well as co-director of On Doctoring at Dartmouth Geisel, Vice Chair of Clinical Affairs at Dartmouth Hitchcock Medical Center, . Aand most importantly for our conversation today, aAssociate dDean of aAdmissions at Geisel.  Dr. Pinto-Powell, welcome to Admissions Straight Talk. [2:08] Thank you. Can you give us an overview of the MD program at Geisel, focusing on its more distinctive elements? [2:17] I think one of the things I'd start off by saying is that Geisel is a small school, relatively. We have 92 students, 90 MD students, two MD/ PhD students, and this is the largest we've ever been. We were a much smaller school, 65 students, until fairly recently, about a decade and a half to two decades ago, and then have grown to 92. I mentioned that because I think that's one of its distinctive elements. It's small enough that in some ways, I would say, we are the “Cheers” of schools where everybody knows your name and everybody's glad you came. And if you ask any of our students or staff or administrators, what is their favorite thing, they will say the sense of community, the sense of feeling like people know you. Our students don't graduate without personally knowing more than 10-15 faculty, have been to their homes, watched their dogs or animals and things like that. I think that makes it just a wonderful place to learn to be a doctor. Sounds like a very close-knit community. [3:35] I believe so. On the website, it mentioned several times that the medical school has a real determination to graduate what they called “the complete physician.” What does that mean, “the complete physician,” and does it tie into the community that you were just talking about? [3:41] It does. It absolutely does. I'm really glad you asked the question because that is our tagline. My silly joke usually is, well, I don't know any medical school in this country or any other that's trying to graduate the incomplete physician. What we mean at Geisel when we talk about the complete physician is somebody who's totally grounded in the foundational science. I think that first point is really relevant and important today. I think we all know that most medical schools have a pass/fail pre-clinical curriculum to stimulate collegi...

Physician Dr. Ira Byock is a voice for change in the hospice industry, and an advocate for quality end of life care. His many years of experience in hospice medicine, coupled with the compassion he has for people dealing with serious illness, have made him an industry leader in the U.S. According to his website (irabyock.org), he is “Founder of the Institute for Human Caring at Providence St. Joseph Health. Dr. Byock is Active Professor Emeritus of Medicine and Community & Family Medicine at the Geisel School of Medicine at Dartmouth. He served as Director of Palliative Medicine at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire from 2003 through July 2013. Dr. Byock has been involved in hospice and palliative care since 1978. His research has contributed to conceptual frameworks for the lived experience of illness that encompasses a continuum from suffering to wellbeing; related measures for subjective quality of life during illness; and effective life-completion counseling methods. From 1996 to 2006 he directed Promoting Excellence in End-of-Life Care, a national Robert Wood Johnson Foundation program that developed prototypes for concurrent palliative care of people with life-threatening conditions. He is a past president of the Academy of Hospice and Palliative Medicine.”   What Dr. Byock's bio doesn't describe is his caring heart. It drives his dedication to identifying the issues we face in the hospice industry and offering evidence-based, practical solutions. He wants the hospice silo of healthcare to correct its own path. Dr. Byock believes hospice can heal its own dysfunction by holding providers and clinicians responsible for the care we provide and how we provide it. His articles in STAT magazine and the Journal of Palliative Medicine describe actionable, practical solutions. Hospice practitioners of every discipline can learn from Dr. Byock.   Connect with Dr. Byock at irabyock.org. Find and purchase Dr. Byock's books, including The Four Things That Matter Most, by clicking here.  Read Dr. Byock's STAT article Hospice Care Needs Saving here.  Read Dr. Byock's article Core Roles and Responsibilities of Physicians in Hospice Care: A Statement by and for U.S. Hospice and Palliative Care Physicians by clicking here.                                                                                      28 Apr 2023https://doi.org/10.1089/jpm.2023.0194   Book podcast host Helen Bauer to speak at your event or conference by sending an email to helen@theheartofhospice.com.  Follow The Heart of Hospice on Facebook, Instagram, and LinkedIn.  Connect with The Heart of Hospice podcast on The Whole Care Network and other caregiving podcasts by clicking here.  Find more podcast episodes from The Heart of Hospice at The Heart of Hospice Podcast (theheartofhospice.com)

Physician Dr. Ira Byock is a voice for change in the hospice industry and an advocate for quality end of life care. His many years of experience in hospice medicine, coupled with the compassion he has for people dealing with serious illness, have made him an industry leader in the U.S.  According to his website (irabyock.org), he is “Founder of the Institute for Human Caring at Providence St. Joseph Health. Dr. Byock is Active Professor Emeritus of Medicine and Community & Family Medicine at the Geisel School of Medicine at Dartmouth. He served as Director of Palliative Medicine at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire from 2003 through July 2013. Dr. Byock has been involved in hospice and palliative care since 1978. His research has contributed to conceptual frameworks for the lived experience of illness that encompasses a continuum from suffering to wellbeing; related measures for subjective quality of life during illness; and effective life-completion counseling methods. From 1996 to 2006 he directed Promoting Excellence in End-of-Life Care, a national Robert Wood Johnson Foundation program that developed prototypes for concurrent palliative care of people with life-threatening conditions. He is a past president of the Academy of Hospice and Palliative Medicine.”   What Dr. Byock's bio doesn't describe is his caring heart.  It drives his dedication to identifying the issues we face in the hospice industry and offering evidence-based, practical solutions.  He wants the hospice silo of healthcare to correct its own path.  Dr. Byock believes hospice can heal its own dysfunction by holding providers and clinicians responsible for the care we provide and how we provide it.  His articles in STAT magazine and the Journal of Palliative Medicine describe actionable, practical solutions.  Hospice practitioners of every discipline can learn from Dr. Byock.   Connect with Dr. Byock at irabyock.org. Find and purchase Dr. Byock's books, including The Four Things That Matter Most, by clicking here.  Read Dr. Byock's STAT article Hospice Care Needs Saving here.  Read Dr. Byock's article Core Roles and Responsibilities of Physicians in Hospice Care: A Statement by and for U.S. Hospice and Palliative Care Physicians by clicking here.                     28 Apr 2023https://doi.org/10.1089/jpm.2023.0194 Book podcast host Helen Bauer to speak at your event or conference by sending an email to helen@theheartofhospice.com.  Follow The Heart of Hospice on Facebook,  Instagram, and LinkedIn.  Connect with The Heart of Hospice podcast on The Whole Care Network and other caregiving podcasts by clicking here.  Find more podcast episodes from The Heart of Hospice at The Heart of Hospice Podcast (theheartofhospice.com)  

Physician Dr. Ira Byock is a voice for change in the hospice industry, and an advocate for quality end of life care. His many years of experience in hospice medicine, coupled with the compassion he has for people dealing with serious illness, have made him an industry leader in the U.S. According to his website (irabyock.org), he is “Founder of the Institute for Human Caring at Providence St. Joseph Health. Dr. Byock is Active Professor Emeritus of Medicine and Community & Family Medicine at the Geisel School of Medicine at Dartmouth. He served as Director of Palliative Medicine at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire from 2003 through July 2013. Dr. Byock has been involved in hospice and palliative care since 1978. His research has contributed to conceptual frameworks for the lived experience of illness that encompasses a continuum from suffering to wellbeing; related measures for subjective quality of life during illness; and effective life-completion counseling methods. From 1996 to 2006 he directed Promoting Excellence in End-of-Life Care, a national Robert Wood Johnson Foundation program that developed prototypes for concurrent palliative care of people with life-threatening conditions. He is a past president of the Academy of Hospice and Palliative Medicine.”   What Dr. Byock's bio doesn't describe is his caring heart. It drives his dedication to identifying the issues we face in the hospice industry and offering evidence-based, practical solutions. He wants the hospice silo of healthcare to correct its own path. Dr. Byock believes hospice can heal its own dysfunction by holding providers and clinicians responsible for the care we provide and how we provide it. His articles in STAT magazine and the Journal of Palliative Medicine describe actionable, practical solutions. Hospice practitioners of every discipline can learn from Dr. Byock.   Connect with Dr. Byock at irabyock.org. Find and purchase Dr. Byock's books, including The Four Things That Matter Most, by clicking here.  Read Dr. Byock's STAT article Hospice Care Needs Saving here.  Read Dr. Byock's article Core Roles and Responsibilities of Physicians in Hospice Care: A Statement by and for U.S. Hospice and Palliative Care Physicians by clicking here.                                                                                      28 Apr 2023https://doi.org/10.1089/jpm.2023.0194   Book podcast host Helen Bauer to speak at your event or conference by sending an email to helen@theheartofhospice.com.  Follow The Heart of Hospice on Facebook, Instagram, and LinkedIn.  Connect with The Heart of Hospice podcast on The Whole Care Network and other caregiving podcasts by clicking here.  Find more podcast episodes from The Heart of Hospice at The Heart of Hospice Podcast (theheartofhospice.com)

Are you curious about palliative care? Do you know what it is or when to ask for it? Palliative care is a field that seeks to improve the quality of life for individuals facing serious illnesses or nearing the end of their lives. In this episode, we explore the world of palliative care with a leading expert in the field, Dr. Ira Byock, M.D. From the evolution of palliative care to the use of psychedelics, this episode will challenge your perceptions and offer new insights into how we can provide the best care possible for those facing life's most challenging moments.“The potential for people to be well as they die should be the next big thing in American culture!”Ira Byock, M.D. is a leading medical authority and public advocate for improving care through the end of life. Dr. Byock is an active emeritus professor of medicine and community & family medicine at Dartmouth's Geisel School of Medicine and has been involved in hospice and palliative care since 1978. His research has contributed to conceptual frameworks for the lived experience of illness; measures for subjective quality of life during illness; and counseling methods for life completion. He is a past president of the Academy of Hospice and Palliative Medicine.From 1996 to 2006 Dr. Byock directed a national grant project of the Robert Wood Johnson Foundation that developed prototypes for concurrent palliative care within mainstream health care. From 2003 to mid-2013, he led the palliative care program at Dartmouth-Hitchcock Medical Center and the Dartmouth health system based in Lebanon, N.H. Dr. Byock has authored numerous articles in academic journals, and his first book, Dying Well, has become a standard in the field of hospice and palliative care. The Four Things That Matter Most is widely used as a counseling tool within palliative care as well as pastoral care. The Best Care Possible presents the potential for health care transformation. Dr. Byock lectures nationally and internationally.Show notes:* What is Palliative Care?* How palliative care has evolved* Treating Sharon who had Cystic Fibrosis* When Richard was hit by a Winnebago* Why treating the whole person is so important* The cost of palliative care is less than you would think* When can you ask for palliative care?* The use of psychedelics in palliative care* The fundamental nature of health and illness is not medical – It's personalLinks and references:* Psychedelic Wisdom* Psychedelic Medicine* The Best Care Possible* Taking Psychedelics SeriouslyWant the episode transcript and video? Join our Tribe!Mind Body Health & Politics is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.https://www.mindbodyhealthpolitics.org/subscribe Get full access to Mind Body Health & Politics at www.mindbodyhealthpolitics.org/subscribe

Eugene Nelson is a professor of community and family medicine at The Geisel School of Medicine at Dartmouth and The Dartmouth Institute for Health Policy and Clinical Practice. He serves as the director of Population Health and Measurement at The Dartmouth Institute and leads a program on new models to advance the coproduction of health care. Nelson is a national leader in health care improvement and the development and application of measures of quality, system performance, health outcomes, value, and patient perceptions. His current work is focused on using patient-centered registries to develop learning health systems capable of coproducing improved health care and innovative science. He leads a Dartmouth team that is conducting national proof of concept demonstration programs for several chronic disease populations including cystic fibrosis, inflammatory bowel disease (IBD), and rheumatology.  In the early 1990's, Nelson and his colleagues at Dartmouth began developing clinical microsystem thinking. His work developing the “clinical value compass” and “whole system measures” to assess health care system performance has made him a well-recognized quality and value measurement expert.He is the recipient of The Joint Commission's Ernest A. Codman award for his work on outcomes measurement in health care. Nelson has been a pioneer in bringing modern quality improvement thinking into the mainstream of health care; he helped launch the Institute for Healthcare Improvement and served as a founding board member. He has authored over 150 publications and is an author of two recent books: Quality by Design: A Clinical Microsystems Approach and Value by Design: Developing Clinical Microsystems to Achieve Organizational Excellence.  He received an AB from Dartmouth College, an MPH from Yale University, and a DSc from Harvard University..Glyn Elwyn, is the director of the Institute's Patient Engagement program. He has assembled an international interdisciplinary team, The Preference Laboratory, examining the implementation of shared decision making into clinical settings, using innovative tools and measures, such as CollaboRATE, a patient experience measure of shared decision making and Observer OPTION, for use on recorded data. Members of the team have led the development of Option Grids™ patient decision aids, tools designed to support collaboration between clinicians and patients.He holds chair appointments at the Scientific Institute for Quality of Healthcare, University Nijmegen Medical Centre, Netherlands, the Cochrane Institute for Primary Care and Public Health, Cardiff University, and at University College London. He is the lead editor of Shared decision making: Evidence Based Patient Choice, Oxford University Press, 3rd edition, 2016. Learn more about The Dartmouth Institute Coproduction Laboratory

In this Episode, we talk with Dr. Andrea Pearson, MD, FAAD. She originally hails from Keene, NH and received her MD degree at Geisel School of Medicine at Dartmouth College. She did an Internal Medicine internship at Saint Vincent Hospital and completed her dermatology residency at the University of Massachusetts Medical School in Worcester, MA. Her clinical interests include caring for underserved communities and patients with chronic skin diseases including eczema, psoriasis, and acne. Dr. Pearson shares with us her experiences, tips for dermatology applicants interested in community service and underserved communities, and more. We hope you enjoy! Learn More: https://mycatholicdoctor.com/resources/doctors/andrea-pearson-md-faad/ Music: District Four by Kevin MacLeod Link: https://incompetech.filmmusic.io/song/3662-district-four License: https://filmmusic.io/standard-license --- Send in a voice message: https://podcasters.spotify.com/pod/show/derminterest/message

Hey, thanks so much to kwebs14 for your super nice review on iTunes the other day. Kwebs wrote: [I have] learned so much, shared so many episodes with colleagues, clients … and gained so much value from regularly listening to [Relentless Health Value]. … Thank you … for providing the platform for so many that believe that we can consistently do better in healthcare. Thanks much for writing this. I think our Relentless Tribe is a unique group, and every day of every week I admire your willingness to hear some things that might be pretty hard to hear because they may hit pretty close to home. Dr. Benjamin Schwartz was talking about the podcast on LinkedIn the other day, and he said he doesn't always agree with guests or the discussion but he always learns something and each episode stimulates and challenges his thoughts and opinions. Yes … to all of this. This is our goal in a nutshell: to help those who want to do better in healthcare to have the insight, the information, the other side of the story, the differing opinion, whatever you need to conceive of the action that you want to take. So, thank you so much to everybody who listens. You are the ones who are going to make a difference, and I thank you from the bottom of my heart for doing what you do every day for patients and communities. Alright, so in this healthcare podcast, we are going to answer an FAQ—a listener question I have gotten a lot lately in various forms. Let me common denominator the inquiry: What does it mean to be clinically integrated, and how does a provider organization/practice/CIN (clinically integrated network) know if they are actually clinically integrated or not? Also, the corollary to this question, which is how do CINs—or anybody, really—know if they are clinically integrated enough to start thinking about taking on downside risk? I asked David Muhlestein this question, and then we talk about his answer for 25 minutes. So, like most things in healthcare, it is filled with nuance; but if I was going to oversimplify his answer in one sentence, it's this: Did the practice change how they are practicing medicine in order to drive predetermined outcomes? This is the litmus test for whether care is integrated. Did practice patterns change within participating entities from whatever they were before to a new way of working? Did the team(s) reorient with a goal to attain some documented patient outcomes, be those outcomes patient satisfaction and/or clinical endpoints and/or functional endpoints? If no sort of fundamental change happened, probably it's a no on the clinical integration question. Another litmus test question I've also heard is this: Is the practice looking to get paid more for successes they've already had in upside risk arrangements with kind of little or no desire to transform the practice into a new practice model? If yes, then again, it's gonna be a no on the clinical integration question. The thing is with all of this … well, let me quote Dr. John Lee, who said this pretty succinctly on LinkedIn recently. He said, “Downside risk fundamentally changes how you have to think as a physician and how you manage your patient cohort. You start thinking about team-based care and using analytics.” Yes … interesting. The point Dr. Lee is making — which is kind of inferred, actually, in the listener questions, so let me just state the obvious, which is so obvious it could easily be overlooked — if you are able to take on downside risk and succeed, you're probably clinically integrated. If you're not, you probably aren't. Said another way (this might get a little chicken and egg-y), do you clinically integrate so that you can get the kind of risk-based contracts that enabled Iora, for example, to represent 5% of One Medical's patient base and 50% of its revenue? I have heard similar profitability stories about ChenMed and Oak Street. They all have capitated downside risk accountable care contracts. And have you seen what some of their leadership teams are minting? Obviously, the capitated downside risk when you're integrated gig can be highly profitable. But ... seems like also the community and outcomes are kind of great. Are they doing well by doing good? I'll grant you I might be convinced based on what I've seen. Galileo is another one. Cityblock. But the fundamental question is, do you integrate first and then go after the contracts? Or is it best to wait until there's a decent accountable opportunity on offer and then, sufficiently incented, change the practice? I do not know. I do know, however, what Scott Conard, MD, said in episode 391. I will poorly paraphrase. He said that if better patient outcomes are desired, there must be clinical integration and practice pattern changes. He said his practice went ahead and instituted these changes to improve patient care and did so within a pretty full-on FFS (fee-for-service) environment. My conclusion with all of this? It takes strong leadership with team-building skills and a strong family/community-centric mission to pull off a successful foray into accountable care with downside risk. These same talented and mission-driven leaders probably could manage to improve patient care and lower costs in an FFS environment as well. The converse of this is also likely true: Weak and ineffectual leaders can make a quadruple nothing burger mess in even the best VBC (value-based care) model. Yes … lots to unpack there. I am interested in your thoughts. In this episode, as mentioned, I am speaking with David Muhlestein, who is the chief research and innovation officer with Health Management Associates, or HMA. He has spent the past decade-plus studying ACOs (accountable care organizations) and value-based care, trying to understand what works, what doesn't, and how you change the business models to be successful under these new models of payment. Here is a short version of David's advice to clinically integrate and be ready for downside risk: ·       Step 1: Understand where you are—this includes doing a very clear-eyed self-assessment. ·       Step 2: Assess the needs of your patient population and focus on things where your capacity meets the needs of the population that you serve in the most impactful way. ·       Step 3: Take the outcome of step 2—which is basically whatcha gonna do to fix the most consequential problems that your patients have—and identify the processes by which you will do this. ·       Step 4: Do not boil the ocean. Start with a subset of patients and figure out the exact plan to do better to manage that population—easier said than done, of course. (Betsy Seals, by the way said something along these exact same lines in the shows giving advice to Medicare Advantage plans. And Karen Root [EP381] also alludes to something similar as she talks about how to socialize innovation. So clearly, this advice can be universalized.) You can learn more by emailing David at dmuhlestein@healthmanagement.com and by connecting with him on LinkedIn.     David Muhlestein, PhD, JD, is chief research and innovation officer for Health Management Associates (HMA). He is responsible for the firm's self-directed research and supports strategic planning and innovation. David's research and expertise center on healthcare payment and delivery transformation, understanding healthcare markets, and evaluating how the broader healthcare system is changing. He is a self-identified data nerd and regularly speaks and writes about healthcare system evolution. David joined HMA via its acquisition of Leavitt Partners in 2021, where he was the chief strategy and chief research officer. Additionally, David is a visiting policy fellow at the Margolis Center for Health Policy at Duke University, adjunct assistant professor at The Ohio State University College of Public Health, and a visiting fellow at the Accountable Care Learning Collaborative. He previously served as adjunct assistant professor of The Dartmouth Institute (TDI) at the Geisel School of Medicine at Dartmouth College. David earned his PhD in health services management and policy, JD, MHA, and MS from The Ohio State University and a BA from Brigham Young University.   07:57 What does it mean to be clinically integrated? 10:23 How does changing practice patterns count as becoming clinically integrated? 11:11 How do you change the delivery of care to get better outcomes? 12:05 What does it mean to see better outcomes when becoming clinically integrated? 14:46 EP176 with Dr. Robert Pearl. 17:42 “Their structure is dictating what they are going to prioritize.” 19:02 “How do you care for the patients that have yet to come and see you?” 20:16 EP391 with Scott Conard, MD. 22:38 “When you're integrated, you realize you're not alone.” 25:50 Why does clinically integrating require a significant mindset change? 28:55 What does this country need to do from a policy perspective for this change? 30:24 EP326 with Rishi Wadhera, MD, MPP.   You can learn more by emailing David at dmuhlestein@healthmanagement.com and by connecting with him on LinkedIn.   @DavidMuhlestein of @HMAConsultants discusses #integratedcare on our #healthcarepodcast. #healthcare #podcast #digitalhealth   Recent past interviews: Click a guest's name for their latest RHV episode! Nikhil Krishnan (Encore! EP355), Emily Kagan Trenchard, Dr Scott Conard, Gloria Sachdev and Chris Skisak, Mike Thompson, Dr Rishi Wadhera (Encore! EP326), Ge Bai (Encore! EP356), Dave Dierk and Stacey Richter (INBW37), Merrill Goozner, Betsy Seals (EP387), Stacey Richter (INBW36), Dr Eric Bricker (Encore! EP351), Al Lewis, Dan Mendelson, Wendell Potter, Nick Stefanizzi, Brian Klepper (Encore! EP335), Dr Aaron Mitchell (EP382), Karen Root, Mark Miller, AJ Loiacono, Josh LaRosa, Stacey Richter (INBW35), Rebecca Etz (Encore! EP295), Olivia Webb (Encore! EP337), Mike Baldzicki, Lisa Bari, Betsy Seals (EP375)      

For many people food is a non-issue. They eat regular meals, snack when they feel the need, indulge now and then but don't beat themselves up about it. But some people develop a strange relationship with food – often one that started in adolescence. It may start innocently enough – a fad diet, a decision to go “gluten free” or become a vegan. But, as we learn in our discussion with Dr. Marcia Herrin in today's episode, for kids with a genetic predisposition for eating disorders, it doesn't take much to set the wheels in motion. She gives us advice on what we can do to help keep an eating disorder from “taking hold” of our teens and tweens and what to do if despite those efforts, we find our child in the grips of a disorder. Dr. Marcia Herrin is a Registered Dietitian Nutritionist with a Masters of Public Health from UC Berkeley and a Doctorate of Nutrition Education from Columbia University. She's a Fellow of the Academy of Eating Disorders, having been bestowed the honor for significant contributions in the field of eating disorders. Dr. Herrin is a Clinical Assistant Professor of Pediatrics at the Geisel School of Medicine at Dartmouth, teaching future pediatricians about eating disorders and is the founder of Dartmouth College's nationally renowned eating disorder treatment program for college students. She also runs a private practice in New Hampshire for the treatment of eating disorders in adolescents and adults. She's also the author of The Parent's Guide to Eating Disorders and Nutrition Counseling in the Treatment of Eating Disorders. For show notes (including resources mentioned in the podcast, source documents and a full transcript, go to https://neurogility.com/37. Speaking of Teens is sponsored by https://neurogility.com.FREE GUIDES :“10 Keys to Unlock Your Teen's Emotional Intelligence”“The Challenging Adolescent Brain” (e-book)“Emotional Awareness Strategies” (for parents)“Why Doesn't My Teen Sleep?” (e-book)“Communication for Teen Cooperation”“6 Things You Should Understand About Your Teen”“Helping Your Teen Overcome Negative Thinking”“Over the past three days, I have been binging your podcast, just finished with episode 14 and will get all caught up in a couple of days.  It's wonderful what you are doing and what you are willing to give away for free.  I just wanted to thank you!  Warrior On!” Speaking of Teens ListenerPlease be sure to share this episode with another mom! New episodes drop every Tuesday.  Follow us on Instagram, Twitter, and FacebookAnn ColemanPrivacy

This episode was made in partnership with the Newborn Medicine subcommitee of the American Academy of Pediatrics - Section on Hospital Medicine.    Course: Hyperbilirubinemia in the newborn 35 weeks or more – Updated Guidelines!  Course Director: Tony R Tarchichi MD  - Associate Professor in Dept of Pediatrics at the University of Pittsburgh School of Medicine Course Director: Alison Volpe Holmes, MD, MS, MPH. - Associate Professor of Pediatrics and of the Dartmouth Institute, Geisel School of Medicine at Dartmouth  This Podcast series was created for Pediatric Hospitalists or those healthcare professionals who take care of hospitalized children.  This episode is Hyperbilirubinemia in the newborn 35 weeks or more – Updated Guidelines! As always there is free CME credit of up to 1.25 AMA category 1 for listening to this podcast and going to the Univ of Pitt site. See the link below.  ______________________________________________________ Objectives: Upon completion of this activity, participants will be able to: Review the treatment of hyperbilirubinemia in the newborn 35 weeks or more. Review the definition of Kernicterus. Review the management and when to escalate care in infants more than 35 weeks old who have hyperbilirubinemia. ______________________________________________________ Released:  12/18/2022, Reviewed 12/18/2022, Expire: 12/18/2023 If you are new to the Internet-based Studies in Education and Research (ISER) website (which is how you will get your CME credit), you will first need to create an account: Step 1. Create an Account https://www.hsconnect.pitt.edu/HSC/home/create-account.do If you have used the ISER website in the past, you can click on the link below and then log onto in order to complete the evaluation for this training: Step 2. To access the test for CME credit: https://cme.hs.pitt.edu/ISER/app/learner/loadModule?moduleId=23974&dev=true Accreditation Statement: The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Pittsburgh School of Medicine designates this enduring material for a maximum of  (1.25)  AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

“I plan to row till my last breath” is a strong endorsement for any sport. Yet we heard this sentiment numerous times at the 2022 Head of the Charles Regatta (HOCR), the rowing world's premier event.  The resulting episode features three remarkable protagonists:  Jules from Portland, Oregon, was introduced to rowing twenty years ago as she battled a recurrence of cancer.  Ping, a traditional Chinese medical doctor, overcame acute knee injuries to return to this year's event.  And Ron, paralyzed from a car accident while cycling, was initially anxious to get on the water while tightly strapped into a rowing seat. (Sure enough, Ron's boat did capsize his first time out.) Tune in for three odysseys on the rewards and challenges of rowing and learn more about this sport of a lifetime that instills many more thousands of rowers around the world with the goal of participating at the Head of the Charles – the sport's annual celebration of competition, teamwork, and community.  Original music by Ryan Adair Rooney SHOW NOTES Experts: Dr. Kristine Karlson, MD: Dartmouth Hitchcock Medical Center Section Chief, Family Medicine; Director, Sports Concussion Program; Associate Professor of Community and Family Medicine, Associate Professor of Orthopaedics, Associate Professor of Pediatrics, Geisel School of Medicine, Dartmouth Doctor Chases Her Olympic Dream: Crew: Kris Karlson finished medical school and still kept up with her training as a rower.  Kristine Karlson Olympic Results 1992  Publications: Rib Stress Fractures in Elite Rowers  Rowing: Sport-Specific Concerns for the Team Physician  Dr. Lisa Russell Lowe, DPT PowerHousePhysio  Dr. Russell Lowe's blog @powerhousephy Resources: Head of the Charles Regatta Adaptive Para Rowing U.S. Adaptive Programs - USRowing  Science of Rowing More at www.mybodyodyssey.com Subscribe to the show so you don't miss an episode! And follow us on: Twitter: @mybodyodyssey Facebook: @mybodyodysseypod Instagram: @mybodyodysseypodcast

There's ongoing debate as to whether some preventative screenings are helpful in the general population because of risk associated with doing procedures and unnecessary treatment leading to higher healthcare costs. A recent study from Poland, Norway, and Sweden showing a relatively similar risk of death from colorectal cancer between screened and unscreened populations highlights this dilemma. We are joined by Dr. Audrey Calderwood, a gastroenterologist at Dartmouth in Lebanon. She is the director of the Comprehensive Gastroenterology Center and Associate Professor of Medicine at Geisel School of Medicine at Dartmouth and the Dartmouth Institute for Health and Policy and Clinical Practice. Her passions from both a clinical and research perspective is colorectal cancer prevention. She will walk us through some of the higlights of the study which we hope will help our listeners make an informed decision. The information shared in this episode is meant for medical education and should not be considered as medical advice.

Margit Berman, Ph.D., LP Listen in to hear how Dr. Bermin became interested in the psychology of women and the psychology of gender.  Her interest in eating disorders was borne through seeing how body image concerns robbed women of achieving beautiful and amazing things in life.    ACT helps us let go of the unproductive struggle   Join in her excitement  - “The world has evolved, culture has come along with me and I feel so ready.”  How do we work with “I don't want to accept myself, I need to lose weight”?  We are taught to judge bodies from a young age and are not privileged to grow up in a culture that values all bodies  INFORMED CONSENT to start with a client who is interested in this work   You want what you think the weight loss will buy.  What about bariatric surgery?  Let go of the healthiest thinking   White clinicians have a lot of work to do    Dr. Margit Berman's Seasonings:  Acceptance Commitment Therapy  Wished I had had earlier and better education on ageism, racism   Women En Large –Laurie Toby Edison -  forgotten foremothers of HAES – Fat women    Bio:  Margit Berman, Ph.D., LP, is the Program Director of the Clinical Psychology PsyD Program at Augsburg University and Assistant Professor of Psychiatry at the Geisel School of Medicine at Dartmouth. In addition to training future psychologists, she conducts research on intervention development in women's health. She wrote the clinician manual and self-help guide for the Accept Yourself! intervention for larger-bodied women with depression.    She is the author of Acceptance-Based Approaches for Weight Concerns and Workbook.      With your host Beth Harrell  IG @beth.harrell.cedss  Supervision Freebies 

Mindfulness Strategies To Calm Stress And Anxiety With Dr. Cindy TsaiDr. Cindy Tsai is a board-certified physician, bestselling author, mindfulness teacher, speaker, and life coach who is committed to helping high-achievers live their best life with ease. She earned BA and MS degrees from Johns Hopkins University and MD degree from the Geisel School of Medicine at Dartmouth. As a physician and patient, Dr. Tsai saw and experienced the impact of chronic stress on the body and was compelled to do more than prescribe medications as a bandaid. Through her own healing journey, she explored and trained in a wide range of solution-oriented therapeutic modalities and now emphasizes taking an integrative approach to wellness. As author of the bestselling book, "So Much Better: Life-Changing Strategies to Develop Calm, Confidence, and Curiosity to Become an Inspiring Success Story", she introduces a radical path to well-being, through creating the Inspiring Success Story MethodTM. This method offers clients a diverse range of mind-body-spirit techniques to expand the possibilities of achieving their dreams. Dr. Tsai is an award-winning physician who has been nationally recognized, featured and published in a range of media including mindbodygreen, US News, Doximity, KevinMD, Medium, and more. She is grateful to share her expertise and passion to guide as many as possible in the journey of self-discovery to recognize the importance of self-care as a wellness practice to lead and enjoy a life of ease.Link to Dr. Tsai's book (https://www.cindytsaimd.com/book or https://www.amazon.com/dp/B09Y4W1JNL?&_encoding=UTF8&tag=cindytsaim0b9-20) and a picture as well. Dr. Tsai also has a free resource guide to "Create Your Own Calm" for those who are interested: https://cindytsaimd.com/calm and all Dr. Tsai's social media platforms are @cindytsaimd (linkedin, instagram, fb, twitter, tiktok, youtube).  Support the showRate the show: If you enjoyed this episode, please consider providing an honest rating of the show here www.mentalhealthtodayshow.com/reviews/new . Disclaimer: The Mental Health Today Show is for educational purposes only and should not be interpreted as therapy. If you are seeking therapy, please contact a licensed therapist for help.

Season 2 | Episode 40 | October 5, 2022Dr. Vahdat is the section chief of Medical Oncology and the interim section chief of Hematology at Dartmouth Cancer Center and a professor of medicine at the Geisel School of Medicine at Dartmouth. She earned her medical degree at Mount Sinai School of Medicine and completed an internal medicine residency at Mount Sinai Hospital, both in New York City. She completed a fellowship in Hematology/Oncology at Memorial Sloan-Kettering Cancer Center in New York City.A translational breast cancer medical oncologist, Dr. Vahdat's expertise is in drug development. She has been involved in the identification, conceptualization, design, and conduct of clinical trials of new therapies in high-risk, adjuvant, and metastatic breast cancer patients since 1994. She has led four separate drug development efforts that lead to FDA approval of three drugs active in metastatic breast cancer.Medical Matters Weekly features the innovative personalities who drive positive change within health care and related professions. The show addresses all aspects of creating and maintaining a healthy lifestyle for all, including food and nutrition, housing, diversity and inclusion, groundbreaking medical care, exercise, mental health, the environment, research, and government. The show is produced with cooperation from Catamount Access Television (CAT-TV). Viewers can see Medical Matters Weekly on Facebook at facebook.com/svmedicalcenter and facebook.com/CATTVBennington. The show is also available to view or download a podcast on www.svhealthcare.org/medicalmatters.Underwriter: Mack Molding

What's important about de novo protein design from an entrepreneurship perspective? Everything. As the founder of AI Proteins, Chris Bahl leads a company focused on building proteins completely from scratch. The research and subject matter itself are nothing new to Chris, but the entrepreneurial side of his work certainly is. From October 2017 to October 2021, Chris served as the head of protein design for the Institute of Protein Innovation, a Boston-based research institution. One month later, however, he and his team opted to leave the research world and launch a new biotech company, AI Proteins. While the primary purpose of academic research in protein design is to learn more about the nature of proteins as they relate to disease, Chris believes the main mission of biotechnology is to cure it—and he definitely wanted to be on the “curing” side. AI Proteins is expanding the possibilities of protein therapeutics by rationally designing entirely new proteins, or as they're officially called, de novo proteins. Using AI-based design and a high-throughput drug-discovery platform, the company creates synthetic proteins from scratch and seeks to optimize a specific protein's activity for a variety of therapeutic applications. The objective is to enable the development of proteins that are inexpensive, durable, highly specific, and can be optimized for oral delivery. Such a lofty goal is what entrepreneurship in its truest sense is really about. It's also a fascinating story to hear in the founder's own words. About our guest: Chris Stahl is the founder and Chief Scientific Officer of AI Proteins, an Andover, Massachusetts-based company focused on ways to harness the power of synthetically designed proteins to cure diseases. The former head of protein design at the Institute for Protein Innovation, Chris is also a lecturer at both the Harvard Medical School and Boston Children's Hospital, as well as a TED Fellow. His areas of expertise include computational protein design, structural biology, biochemistry, and in particular, he is credited for inventing the de novo design of synthetic miniproteins. He holds a PhD in Biochemistry from the Geisel School of Medicine at Dartmouth. About NBN: The NBN Entrepreneurship and Leadership podcast aims to educate, inform and entertain, sharing insights based on the personal stories of carefully selected guests—all in an informal atmosphere of unscripted conversations and open, personal accounts. Find links to past episodes here. About our Hosts: Kimon Fountoukidis: Kimon is the founder of both Argos Multilingual and PMR. He founded both companies in the mid-90s with zero capital, and both have gone on to become market leaders in their respective sectors. Kimon was born in New York and moved to Krakow, Poland in 1993. He is passionate about sharing his success with others and working entrepreneurs of all kinds to help them achieve their goals. Listen to his story here. On Twitter. On LinkedIn. Richard Lucas: Richard is a business and social entrepreneur who has founded or invested in more than 30 businesses, including Argos Multilingual, PMR and, in 2020, the New Books Network. Richard has been a TEDx event organiser for years, supports the pro-entrepreneurship ecosystem, and leads entrepreneurship workshops at all levels. He was born in Oxford and moved to Poland in 1991, where continues to invest in promising companies and helps other entrepreneurs realise their dreams. Listen to his story in an autobiographical TEDx talk. On Twitter. On LinkedIn. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

What's important about de novo protein design from an entrepreneurship perspective? Everything. As the founder of AI Proteins, Chris Bahl leads a company focused on building proteins completely from scratch. The research and subject matter itself are nothing new to Chris, but the entrepreneurial side of his work certainly is. From October 2017 to October 2021, Chris served as the head of protein design for the Institute of Protein Innovation, a Boston-based research institution. One month later, however, he and his team opted to leave the research world and launch a new biotech company, AI Proteins. While the primary purpose of academic research in protein design is to learn more about the nature of proteins as they relate to disease, Chris believes the main mission of biotechnology is to cure it—and he definitely wanted to be on the “curing” side. AI Proteins is expanding the possibilities of protein therapeutics by rationally designing entirely new proteins, or as they're officially called, de novo proteins. Using AI-based design and a high-throughput drug-discovery platform, the company creates synthetic proteins from scratch and seeks to optimize a specific protein's activity for a variety of therapeutic applications. The objective is to enable the development of proteins that are inexpensive, durable, highly specific, and can be optimized for oral delivery. Such a lofty goal is what entrepreneurship in its truest sense is really about. It's also a fascinating story to hear in the founder's own words. About our guest: Chris Stahl is the founder and Chief Scientific Officer of AI Proteins, an Andover, Massachusetts-based company focused on ways to harness the power of synthetically designed proteins to cure diseases. The former head of protein design at the Institute for Protein Innovation, Chris is also a lecturer at both the Harvard Medical School and Boston Children's Hospital, as well as a TED Fellow. His areas of expertise include computational protein design, structural biology, biochemistry, and in particular, he is credited for inventing the de novo design of synthetic miniproteins. He holds a PhD in Biochemistry from the Geisel School of Medicine at Dartmouth. About NBN: The NBN Entrepreneurship and Leadership podcast aims to educate, inform and entertain, sharing insights based on the personal stories of carefully selected guests—all in an informal atmosphere of unscripted conversations and open, personal accounts. Find links to past episodes here. About our Hosts: Kimon Fountoukidis: Kimon is the founder of both Argos Multilingual and PMR. He founded both companies in the mid-90s with zero capital, and both have gone on to become market leaders in their respective sectors. Kimon was born in New York and moved to Krakow, Poland in 1993. He is passionate about sharing his success with others and working entrepreneurs of all kinds to help them achieve their goals. Listen to his story here. On Twitter. On LinkedIn. Richard Lucas: Richard is a business and social entrepreneur who has founded or invested in more than 30 businesses, including Argos Multilingual, PMR and, in 2020, the New Books Network. Richard has been a TEDx event organiser for years, supports the pro-entrepreneurship ecosystem, and leads entrepreneurship workshops at all levels. He was born in Oxford and moved to Poland in 1991, where continues to invest in promising companies and helps other entrepreneurs realise their dreams. Listen to his story in an autobiographical TEDx talk. On Twitter. On LinkedIn. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/entrepreneurship-and-leadership

Meet Amber Barnato, M.D.:Amber Barnato, M.D. is the John E. Wennberg Distinguished Professor and the Director of The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth. She is trained in two medical specialties, public health and preventive medicine, and hospice and palliative medicine. Dr. Barnato received a bachelor's from the University of California at Berkeley, an M.D. from Harvard Medical School, an MPH from the University of California at Berkeley, and an MS from Stanford University. Key Insights:Amber Barnato, M.D. explores how her medical career experiences led her to the focus of palliative and end-of-life care.  Expanding Horizons. Dr. Barnato took a year before medical school to be a research assistant and speech writer for Assistant Surgeon General Dr. McGinnis. That experience expanded her horizons, exposing her to the policy process, and Dr. McGinnis served a sponsor, improving her medical school candidacy.Path to Palliative Care. Dr. Barnato was morally distressed by the end-of-life care she saw in her general surgery internship, which lacked emotional support, conversations with family, and concerns over quality of life. After listening to a story about end-of-life care research on the radio, she decided she wanted to join the research effort herself. Next Steps for the Dartmouth Atlas. The Dartmouth Atlas focuses on overuse and unwarranted variation of healthcare. However, Dr. Barnato wants the Atlas to expand to underuse and unjust variation. She would like to see a focus on health equity.  This episode is hosted by Joanne Conroy, M.D. She is a member of the Advisory Council for Her Story and is the CEO and President of Dartmouth-Hitchcock and Dartmouth-Hitchcock Health. Relevant Links:Learn more about Dr. Barnato and her researchFollow Dr. Barnato on Twitter

Today's guest is Dr. Bill Hudenko. Dr. Hudenko is a licensed psychologist who has extensive clinical experience working with children who have disruptive-behavior disorders and autism-spectrum disorders. Dr. Hudenko is is a Research Assistant Professor in the Department of Psychological & Brain Sciences at Dartmouth College, an Adjunct Assistant Professor of clinical psychology at Dartmouth's Geisel School of Medicine. He is also an entrepreneur and innovator in the area text-based behavioral health care. In this interview, we talk about how he came to the field of psychology, his research into laughter, and how his love of technology, and desire for an iPad, led him to explore text-based psychotherapy, and ultimately set him on the road to being an entrepreneur in the field of behavioral health. You'll hear me say, “wow!” a lot in this interview because Dr. Hudenko's research and entrepreneurial efforts, especially now with his role at K-Health, seem to promise real improvements in cost, access, and quality for healthcare. For more information, please go to https://healthleaderforge.blogspot.com/2022/08/dr-bill-hudenko-phd-global-head-of.html

Marcia Herrin, EdD, MPH, RDN, LD, FAED How does a dietitian provide family based care virtually? What is Dr. Herrin's opinion about meal plans? Is focusing on weight as a clinician disordered? The reason our guest joined every insurance panel and fights for coverage. Virtual Best Practices episode with Jessica-Lauren Newby Marcia's Seasonings: Chris Fairburn early book on CBT Reiff and Reiff "Notebook" Book “White Fragility”   Bio: Marcia Herrin, EdD, MPH, RDN, LD, FAED, developer of the Rule of Threes Food Plan and author of Nutrition Counseling in the Treatment of Eating Disorders and The Parent's Guide to Eating Disorders. Dr. Herrin is a registered dietitian nutritionist with a doctorate in nutrition education and master's in public health nutrition. Dr. Herrin is Clinical Professor at Geisel School of Medicine at Dartmouth in the US and has provided outpatient nutrition therapy for eating disorders for over 35 years. Her international work is focused on training professionals in the nutrition treatment of eating disorders. Dr. Herrin received her doctorate in nutrition education from Columbia University. At the University of California-Berkeley, she received her masters degree and completed a dietetic internship. Marcia was honored as a fellow in the Academy for Eating Disorders in 2013. Coupon code for clinicians  - bethharrell MyClearStep With your host Beth Harrell

This week we discuss cilia length, ciliopathies and Chlamydomonas reinhardtii (also known as ‘Chlamy') with Brae Briggs (@BiggeBrae), a graduate student from at Dartmouth (@dartmouth),Geisel School of Medicine (@GeiselMed). We find out about a range of ciliopathies, the main composition of cilia as well as using ‘Chlamy' as a model to study cilia length. We also discuss the difficulties of moving in the middle of a PhD and pandemic, open science principles including preprints as well as how we try to have healthy work life balance. Read the full preprint: https://www.biorxiv.org/content/10.1101/2022.04.18.488674v1.full This episode was produced by Emma Wilson and edited by John D Howard. If you enjoyed this show then hit that subscribe button and leave a review (on Apple Podcasts or Spotify). If you love what we are trying to do then buy us a coffee https://www.buymeacoffee.com/preprints! Any contribution is greatly appreciated. For the latest podcast news and updates follow us on Twitter @MotionPod or visit our website; www.preprintsinmotion.com. Produced by JEmJ Productions (find us on Twitter: Jonny @JACoates, Emma @ELWilson92, John @JohnDHoward8) and generously supported by ASAPbio (https://asapbio.org | @asapbio_).

Erika T. Brown, PhD, joins us on this week's reunion episode of the Faculty Factory Podcast. We interview Dr. Brown about her new position with Geisel School of Medicine and much more. In September 2021, Dr. Brown was appointed the new Dean of Faculty Affairs with the Geisel School of Medicine at Dartmouth University in Hanover, New Hampshire. Dr. Brown has many years of experience in faculty affairs, professional development, and academic medicine. This is the second time she has joined our show for an interview, but it has been well over three years since Dr. Brown last spoke with us on the Faculty Factory. In March 2019, Dr. Brown was Associate Dean for Faculty Affairs & Development at Morehouse School of Medicine in Atlanta when she first appeared on our podcast. Today's episode is another reunion episode where we welcome back guests from past episodes to share ideas, lessons learned, etc. If you are interested in listening to Dr. Brown's first interview with us on the Faculty Factory, you can access that here: https://facultyfactory.org/erika-t-brown/

This week we're talking with Wiley “Chip” Souba, MD, on the Faculty Factory Podcast. Dr. Souba joins us for a discussion about the inward journey of leadership. As Dr. Souba puts it: leading yourself is the prerequisite to being an effective leader of others. “It's a journey because it's a lifelong endeavor, a mountain with no top. And it's about leadership because it's about leading yourself.” Dr. Souba is a Professor of Surgery with the Geisel School of Medicine at Dartmouth College in Hanover, NH. He has also held other prestigious positions with Dartmouth College, including: Former Dean of the Geisel School of Medicine Former Vice President for Health Affairs Learn more: https://facultyfactory.org/chip-souba 

Dr Laura Roberts is joined by Professor Douglas Noordsy, M.D., from the Geisel School of Medicine at Dartmouth, to discuss his book Lifestyle Psychiatry (2019) which examines the impact of lifestyle interventions -from exercise, yoga, and tai chi to mindfulness and meditation, diet and nutrition, and sleep management- on psychiatric disorders, including depression, anxiety, post-traumatic stress disorder, schizophrenia, and addiction. With chapters that focus on developing a robust therapeutic alliance and inspiring patients to assume responsibility for their own well-being, Dr. Noordsy's book provides a framework for lasting, sustainable lifestyle changes. In this episode: Introduction (0:15) Genesis of the book (1:30) Evidence for lifestyle as a valid area for treatment (3:00) Structure of the book (4:00) Defining and defending the lay-term “lifestyle” (9:15) Treating psychosis with exercise (11:35) Intervening Early in Psychosis (book) (17:35) Call to action for lifestyle psychiatry as a vital discipline (21:00) Consciously avoiding judgmental stances (24:25) Resources: Lifestyle Psychiatry (2019) - American Psychiatric Association Publishing Intervening Early in Psychosis (2019) - American Psychiatric Association Publishing To learn more about Dr. Noordsy, please visit: https://profiles.stanford.edu/douglas-noordsy Other APA podcasts: www.psychiatryonline.org/podcasts

In part one, of this two-part ASCO Education podcast episode, host Dr. Jeremy Cetnar (Oregon Health & Science University) interviews two very accomplished physicians and researchers, Dr. Lauren Abrey and Dr. Jason Faris. We'll hear about their motivations for pursuing medicine and how they arrived at the different positions they've held in academia and industry.  If you liked this episode, please subscribe. Learn more at https://education.asco.org, or email us at education@asco.org.   TRANSCRIPT   Dr. Jeremy Cetnar: Hello, and welcome to the ASCO Education podcast episode on career paths and oncology. My name is Jeremy Cetnar. I'm a Medical Oncologist and Associate Professor of Medicine at Oregon Health and Science University in Portland. I'm delighted to introduce today's two guests, whose careers in oncology have crisscrossed academia and industry. Dr. Lauren Abrey and Dr. Jason Faris, I'm excited to chat with you about the inspiration and motivations that drive you, people you've leaned on, how you've made your career decisions, challenges you've faced, and more.  So let's start by asking each of you, could you share a little bit about your early life and background, what attracted you to medicine, and who are some of your early mentors and role models? Let's start with you, Dr. Faris.  Dr. Jason Faris: Yeah, I'd be happy to. Thank you. So, I grew up in a small town in South Jersey in Greater Philadelphia. My mom was a registered nurse in pediatrics in the maternal infant unit for many years at Cooper Hospital. I was always interested in science and medicine and my mom's dedication to her patients. Her altruism and compassion served as a real inspiration for me, for my eventual decision to go to medical school. But I took a long time to get there. I had a bit of a circuitous route to arrive to my career in medicine though it started off conventionally enough. I was initially geared towards a premedical track in college, majoring in biology, but an exciting summer research project, working on the biochemical mechanisms underlying osmoregulation in a marine crustacean with mentoring from my first true mentor, Dr. Don Lovett, led me to apply to and attend graduate school in molecular biology at Princeton.  This was followed by a position at Merck as a molecular biologist in the genetic and cellular toxicology group. I went to veterinary school at the University of Pennsylvania where I met my future wife. And then finally, back to the original plan of attending medical school, but I have to say with a much better sense of why I wanted to attend medical school in the first place, now in my late 20s, which was a bit unconventional at the time. I really did my fair share of exploration of Allied Health careers. That's for sure. I attended Johns Hopkins for medical school, where I quickly discovered a passion for internal medicine. And that was far and away my favorite clerkship and sub-internship. That's the background to how I got to medical school.  Dr. Jeremy Cetnar: Dr. Abrey?  Dr. Lauren Abrey: Interesting. I love your story. We share... I grew up in a small town, not so far away, but I was in upstate New York. And I think there were two influences that kind of got me to my ultimate passion for brain tumors. And this sounds a little quirky to start with. But I had a pretty serious head injury as a tween. So I guess I was about 12. I had a skull fracture, epidural hematoma. And while I would never have said I woke up at that moment and thought I have to be a doctor, I think I became fascinated about things to do with the brain.  In parallel, something that I think tinged a lot of my childhood was a number of family members who had cancer. So both of my grandmothers had breast cancer, while I was well aware of the fact that they were sick and battling this. And two of my aunts also had cancer. And I would say it's an interesting split in my family. So about half of them are survivors and about half ultimately died of their disease.  So both of these things really motivated me or focused me on the need to do something important, but also to do something that really motivated me to get out of bed in the morning. I think I was much more to the point. I went straight to college, straight to medical school. I remember calling my parents and telling them I was applying to medical school and having them say, “Wait. You? Really?” So it wasn't necessarily the family expectation that I would do this, but I was very driven and motivated to make some of these choices and then discover my particular interests as I progressed through medical school. So I went to Georgetown for medical school and then have trained at a number of places in the US. I think that's a little bit how I took my first step on this career journey, let's say.  Dr. Jeremy Cetnar: So take us through what the decisions were like in your head at the end of fellowship in terms of first jobs. Dr. Faris?  Dr. Jason Faris: In terms of my choice to pursue a career in medical oncology, this goes back to medical school during an internal medicine clerkship. I had an assistant chief of service, ACS, at the time, Phil Nivatpumin. He'd go on to become a medical oncologist. He really inspired me with his optimism and bedside manner, including with multiple oncology patients on that clerkship. His enthusiasm for science and medicine, his teaching skills, and an absolutely legendary fund of knowledge. For Phil, he was just an incredible ambassador for both internal medicine and for oncology.  After medical school, I went to internship and residency at Mass General Hospital. And in one of my first rotations, I was on the oncology service, which was not so creatively called Team Three. I think they can up the ante there, but oncology services on Team Three. I was caring for many extremely ill patients battling disease progression from their metastatic cancers, or sadly, in many cases complications of their treatments. During that rotation, I was intrigued by clinical trials offering novel treatment options based on cutting edge science, but also struck by the number of patients who just didn't have any clinical trial options. I became aware of the limitations of the conventional treatments that were offered.  I was really inspired by the patience and dedication of the nurses and doctors caring for them. And I vividly recall a roughly 50-year-old woman I helped care for with AML, watching as the 7+3 chemotherapy caused lots of side effects for her and being amazed by her strength and grace, her resilience as she faced her illness, her potential mortality, and the intense chemotherapy she was undergoing. And I knew during those moments with that leukemia patient while caring for other patients on that oncology service that this was the field I would pursue. Oncology was really the perfect blend of humanism, problem solving, longitudinal follow-up and rapidly accelerating scientific progress leading to new avenues for clinical trial treatments.  Like Lauren, I was motivated and inspired by cancer diagnoses in my own family. My maternal grandmother died of pancreatic cancer during my junior year of college. My dad was diagnosed with colon cancer during my first year of fellowship. So those are all really strong motivators, I would say. And after completing my fellowship at the combined Dana-Farber MGH program, my first position out of fellowship was in the gastrointestinal cancer group at MGH. I actually had been training in genitourinary oncology after my main clinically focused year of fellowship, but I did a chief resident year in the middle of fellowship, and that was the tradition at MGH. And as I was about to return to fellowship for my senior year of fellowship, the head of the GI Group and head of the Cancer Center at the time, Dave Ryan, offered to serve as a clinical research mentor for me in GI cancers. As a senior fellow, I wrote an investigator-initiated trial of cabozantinib for patients with neuroendocrine tumors under his mentorship that went on to demonstrate encouraging results, led to a Phase III study in that cancer population, and I ultimately accepted a position at the MGH Cancer Center in the GI cancer group about 11 years ago. And that was the start of my post-training career.  Dr. Jeremy Cetnar: And how about you, Dr. Abrey?  Dr. Lauren Abrey: So for people who don't know, I'm actually a neurologist. I finished my training in neurology and then pursued a fellowship in neuro oncology. I would say it was really patients and observations of things that were happening with patients during my residency. I did my residency at the University of Southern California at Los Angeles. I was at the LA County Hospital, which for people who don't know, is one of the largest hospitals in the country. I had the chance to see several patients who had paraneoplastic syndromes, and got the support from different faculty members to write those cases up, and really resulting in my first independent publications. That was what kind of got me bitten by the bug to understand this link between neurology and oncology.  I very intentionally went to Memorial Sloan Kettering to have the opportunity to work with Jerry Posner. And I think I no sooner got there than I got totally bitten by the brain tumor bug, which seems a little counterintuitive. But the paraneoplastic work was kind of deep laboratory work. And I realized that I really enjoyed seeing the patients having the partnership with neurosurgeons and digging into what is still a pretty intense unmet medical need.  So it was an interesting pivot because I really thought I was going to Sloane to focus on paraneoplasia. I still think I learned so much with that interest that I think we can reflect on when we consider how immunology has finally entered into the treatment landscape today for different tumor types and understanding is there a background in paraneoplastic disorders that could help us. But I have to say it was really the brain tumor work that got me focused and the chance to work with people like Lisa DeAngelis, Phil Gutin, and others that was kind of fundamental to my choices. I stayed there for two years of fellowship and then continued as faculty for about another 15 years at Sloan Kettering. So that's really the start of my academic career and the pivot to industry came much later.  Dr. Jeremy Cetnar: So both of you have impressive career CVs, have been trained at very prestigious institutions. So at some point in time, take me through, what was that transition like between, 'Hmm, what I'm doing is enjoyable, but maybe there's something else out there that I want to explore.' And what I mean by that is mostly industry at this point. So that's an important question that I think a lot of junior faculty face, a lot of mid-career faculty, maybe even later-stage faculty. But I think that's a tension point for a lot of people because I think there's a lot of fear. I think there's a lot of anxiety about moving outside of the academic realm. So, tell us a little bit about what was the pull in terms of going to industry and what were some of the thought processes that were going on. Dr. Faris?    Dr. Jason Faris: I've experienced two transitions, actually, between academia and industry. I like to do things in pairs, I guess. But the first was, after multiple years at the MGH as a resident fellow and as a clinical investigator at the MGH Cancer Center. As a new attending and clinical investigator, I was attempting to balance my work priorities, providing patients with GI cancers, which is a rewarding but complex and I'd say emotionally intense experience, given the phenomenally aggressive and devastating cancers these patients grapple with such as pancreatic cancer, alongside the other responsibilities of my clinical investigator position.  Those other responsibilities included writing grants and papers and protocols, evaluating patients who were interested in open clinical trials, and serving as the principal investigator for multiple studies. I was serving on committees, mentoring and teaching. Patient care was always my top priority as it should and really must be. And I feel incredibly lucky to have had truly amazing colleagues at MGH across several disciplines, from medical oncology, nurse practitioners, practice nurses, radiation oncologists, and surgeons. It was and continues to be a dynamic place full of extremely talented and dedicated clinicians. I think we really all benefited from the coordinated teamwork in both patient care and research in a really tight-knit GI Group.  But nonetheless, for me as someone who delighted in spending large amounts of time with my patients in the clinic rooms, and I think my colleagues would agree frequently agonizing over decisions impacting their care, achieving sufficient balance to really focus on writing and overseeing clinical trials was becoming increasingly challenging for me. And it was in that context, after spending roughly a decade and the combination of residency fellowship training and as an attending in the GI cancer group all at MGH that I made a truly difficult decision to move from my beloved outpatient clinical and clinical investigator role to industry to focus more exclusively on clinical research.  And after interviewing for several industry-based roles, I accepted a position in the early-phase group at the Novartis Institutes for Biomedical Research or NIBR as we kind of pronounced those words in Cambridge. I absolutely loved my time at NIBR. It's an incredible place with a strong history of and commitment to innovation as well as passionate, talented colleagues, many of whom I've worked with in the past. When I first started at Novartis, I was amazed at the array of experts on the teams I was helping to lead as a clinical program leader. Our teams are the definition of multidisciplinary. They're composed of what we call line function experts in multiple disciplines. This includes preclinical safety experts who design and analyze data from studies that precede the filing of an IND, research scientists, chemists, preclinical, and clinical pharmacologists, statisticians, program managers, drug and regulatory affair colleagues, who focus on the interactions with health authorities, including the FDA, operational colleagues called clinical trial leaders, and many others.  In my role as a senior clinical program leader, I also have the opportunity to collaborate frequently with research colleagues on preclinical programs, designing and writing first in human trials, followed by conducting the actual studies and in close collaboration with our academic colleagues, analyzing the clinical and translational results.  Dr. Jeremy Cetnar: Dr. Abrey, how about you? Was there a moment or what were the moments that led to you deciding to make this transition?  Dr. Lauren Abrey: I guess I have the other sort of story. I got pushed, I would say, in the sense that like many of us, I'm married, and my husband was the one who took a job with Novartis and said, “This would be an adventure. Let's go live in Switzerland.” So similar to Jason, he took a position at NIBR, and I think for many of the same reasons, he really wanted to delve deeply into early mechanism of action and allow himself to dedicate really a chunk of his career to developing key drugs. But moving to Switzerland changes your options suddenly. I think I had spent most of my career at Sloan Kettering doing clinical trials. That was really my comfort zone, my sweet spot. And when we moved over here, I explored briefly, could I set up an academic career here?  And very kindly, I was invited by a number of Swiss colleagues to look for opportunities to do that. But I realized what I loved was talking to patients, and that that was going to be difficult with the language barrier. And I equally loved running clinical trials. So I had a great opportunity to join Roche shortly after their merge or full acquisition of Genentech. This allowed me to continue the work I had been doing on Avastin for brain tumors.  But I think the other thing that allowed me to do, that was something I was really looking for was to broaden my scope and to no longer be niched as just a brain tumor expert. And if you're in academia and you're a neurologist, obviously, you're going to be fairly constrained in that space. But moving into a role in industry really allows you to look much more broadly and work across multiple tumor types. And I spent the next seven years at Roche running not just the Avastin teams that were developing drugs for a number of indications, but really overseeing the clinical development group based in the European sites. And they had about 14 different drugs in different stages of development as well as partnerships with their early research group that was European based.  So it was a fascinating time for me, and I feel kind of like I got thrown into the pond. I knew a lot about clinical trials. I had no idea about so many other aspects of what I needed to consider. And I think Jason started to allude to some of this with the different line function expertise and things I think we take for granted or maybe we simply have blind spots around them when we are sitting in our academic organizations. So it's been a really delightful plunge into the pool. I've continued to swim mostly. Occasionally, a little bit of drowning, but a lot of fun.  Dr. Jeremy Cetnar: What would you say are the major differences between an academic career and industry?  Dr. Lauren Abrey: I think, as you said, the things that are similar is that the purpose or the mission for both is in many ways the same. We would like to develop better treatments for patients with cancer. And so there's a huge focus on clinical trials. There needs to be a huge focus on patients, and that can get diluted in industry. I think the things that you don't appreciate sometimes when you're sitting on the academic side is just really the overarching business structure and the complexity of some of the very large organizations. So you suddenly are in this huge space with people focused on regulatory approvals focused on pricing, focused on manufacturing, focused on the clinical trial execution, and why you are doing it in different spots.  And so I think some of the different factors that you have to consider are things that again, we either take for granted or are super focused when you're in one organization. And I think the tradeoffs and how decisions are made, particularly in large pharma, can be frustrating. I think we are all used to applying for grants or getting the funding we need to do whatever our project or trial is. And then you just start very laser focused on getting to the end. If you're in a large organization and they have a portfolio where they're developing 14, 15, 20 different things, you might suddenly find that the project you think is most important gets de-prioritized against something that the company thinks is more critical to move forward. And that could be because there's better data, but it could also be because there's increasing competition in the space or there's a different pull for a large company. I haven't seen the early development side as much. I've seen the development. I've now seen Medical Affairs for how some of those decisions are made, but I'd be curious to hear what Jason has seen in some of his experiences as well.  Dr. Jason Faris: Comparing and contrasting a little bit between the two, because I've run early phase studies on the academic side, I'll talk more about that in a little bit in terms of another academic position that I held. So I've run early-phase studies there. I've run early-phase studies in industry as well. And they share a lot of similarities, certainly following compelling science, the excitement about new therapies that are going to be offered to patients. But I think the execution is a bit different, and I would say, when you're running clinical trials in the academic setting, you're meeting every patient that you're going to put on study or at least one of your colleagues is, if you have sub-eyes on the study, that's a major, major difference, right? You're directly taking care of a patient going on to an experimental therapy, consenting that patient, following them over time, getting the firsthand experience and data from that patient interaction, but not necessarily, unless you're running an investigator-initiated study, not necessarily having access to the data across the whole study.  You're hearing about the data across the whole study at certain time points on investigator calls, PI meetings, dose escalation meetings, those kinds of things. But you're not necessarily having access to the real-time emergence of data across the whole study from other people's patients. So you're a bit dependent on the sponsor to provide those glimpses of the data, synthesize that and present overview. So those are some operational differences, I would say, because you're not taking direct care of the patients and having your time split among different commitments in that way I have felt a greater ability to focus on the clinical research that I'm doing in my industry-based role, which I like, of course, but I also miss taking care of patients. I love taking care of patients.   So I think it's always a double-edged sword with that if we can use a sword analogy here. But I think they both offer really exciting options to pursue new therapies for patients, which for me, was one of the fundamental reasons that I pursued medical oncology in the first place. It was really this idea that the field is rapidly advancing. I wanted to be a part of that. I saw firsthand what cancer could do to my family or family members, and I took care of patients in the hospital as an intern resident and fellow where I think there's just a tremendous unmet medical need. And so having an opportunity to contribute to the development of new therapies was always a real inspiration for me.  Dr. Jeremy Cetnar: With that being said, what led you to go back into academia?  Dr. Jason Faris: This is an ongoing saga, I guess. So after several years of professional growth at Novartis, gaining experience with designing and conducting clinical trials on the industry side, I was actually at ASCO and I learned of an open role for the director of the early phase trials program at Dartmouth's Cancer Center. After extensive consideration, which I think you can see as my trademark at this point, I made another difficult decision to interview for the position, which was focused on helping to grow the early phase trials program at an NCI comprehensive designated cancer center that's unique in a way because it's in a rural area. And it had a new director of the Cancer Center, Steve Leach, who's a renowned laboratory scientist with a focus on pancreatic cancer and a surgeon by training.  I ultimately decided to accept the early phase director position, moving my family away from Greater Boston, where we had lived for about 15 years, to the upper valley of New Hampshire. And while at Dartmouth, I was part of exciting projects, including writing and overseeing an NCI grant called Catch Up, which was geared towards improving access to early phase clinical trials for rural patients. I opened numerous sponsor-initiated immunotherapy and targeted therapy, early phase trials. Just to say a little bit about Dartmouth's Cancer Center - I think they also benefit from tremendous collaboration, this time across Dartmouth College, the Geisel School of Medicine, the School of Public Health. I think they provide really excellent care to their cancer patients. And I was extremely proud to be part of that culture in the GI Group, which was much smaller than the one at MGH, but also an incredibly dedicated group of multidisciplinary colleagues who work tirelessly to care for their patients.  But nonetheless, less than six months into that new position, the COVID pandemic started, and that introduced some significant and new challenges on the clinical trials side in terms of staffing, infrastructure, those kinds of things. In that context, I made a decision to return to NIBR, refocus on clinical research, and hope to harness my background in running clinical trials in both settings, both academic and industry, as well as the resources and pipeline of Novartis to really maximize my impact on drug development. So for me, it was a question of where can I have the maximum impact at this crazy time, difficult time. I saw that my best option was to return to industry to work on studies to try to develop new therapies. Broadly speaking, my role as a senior clinical program leader in the translational and clinical oncology group at NIBR is to design, write, conduct, and analyze innovative clinical trials of early phase therapeutics.  Dr. Jeremy Cetnar: Wow, that's fascinating, very, very interesting. A lot of stress. You should definitely be buying lots of presents for your family for moving them all over the place.  This concludes part one of our interview with Drs. Abrey and Faris. Thank you so much for sharing your inspiring career stories. And thank you to all our listeners for tuning into this episode of the ASCO Education Cancer Topics podcast.  Thank you for listening to the ASCO Education podcast. To stay up to date with the latest episodes, please click subscribe. Let us know what you think by leaving a review. For more information, visit the Comprehensive Education Center at education.asco.org.    The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. 

According to the CDC scientists are curently tracking multiple cases of monkeypox that have been reported in several counties that don't normally report the disease, including the United States. In this episode host Jessica Swain talks to Dr. Elizabeth Talbot, infectious diseases physician at Dartmouth Health and professor of medicine at the Geisel School of Medicine, with hopes to increase awareness and provide knowledge for healthcare providers and patients who experience rash illnesses suspicious for monkeypox. The information shared in this episode is meant for medical education and should not be considered as medical advice.

Season 2 | Episode 21 | May 25, 2022Amber E. Barnato, MD, MPH, MS, director of the Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth, is the next guest on Medical Matters Weekly  on Wednesday, May 25. The show will cover Barnato's wide range of expertise, including public health/preventive medicine, hospice/palliative medicine, the institute's work, health equity, and Barnato's research regarding life support decisions families and physicians make for patients in the ICU.In addition to her role as director of the Dartmouth Institute, Barnato is the John E. Wennberg Distinguished Professor at the Geisel School of Medicine at Dartmouth. The Institute is both an academic department and a cross-campus institute bringing together more than 150 faculty who serve the mission of improving health and health care by conducting research jointly with staff and academic, health system, and community partners and by teaching and learning from more than 200 graduate students annually in the department's MS, MPH, MHCDS, and PhD programs.Barnato is trained in two medical specialties, public health/preventive medicine and hospice/palliative medicine.  Her own research focuses on understanding the causes and consequences of variation in end-of-life intensive care unit (ICU) and life-sustaining treatment use among seriously ill older adults. She focuses on the interplay between organizational norms, provider-patient communication, and implicit cognition, and how these phenomena produce racial disparities in end-of-life treatment.Medical Matters Weekly features the innovative personalities who drive positive change within health care and related professions. The show addresses all aspects of creating and maintaining a healthy lifestyle for all, including food and nutrition, housing, diversity and inclusion, groundbreaking medical care, exercise, mental health, the environment, research, and government. The show is produced with cooperation from Catamount Access Television (CAT-TV). Viewers can see Medical Matters Weekly on Facebook at facebook.com/svmedicalcenter and facebook.com/CATTVBennington. The show is also available to view or download a podcast on www.svhealthcare.org/medicalmatters.Underwriter: Mack Molding

In this healthcare podcast, we're gonna zoom out and look at the entire healthcare industry. I am very confident that you know a lot about the healthcare industry and its basic stats. It's huge. The healthcare industry is approaching the $4 trillion mark, and it employs more people than any other industry in 47 states. Think about that momentarily. More people work in healthcare than in any other industry in every state except for Wisconsin, Indiana, and Nevada. We could get into (but we won't) how many of the gigantic, consolidated incumbents in the healthcare industry are either for-profits sporting very happy shareholders or investors. Then, of course, we have our “nonprofits”—especially mega-nonprofit health systems—who enjoy some pretty healthy margins while, at the same time, these health systems in general offer up some fairly embarrassing levels of charity care considering the amount of taxes they deprive their communities of. You also are probably eminently familiar with various ways that have been cited to transform the industry. So, the usual suspects here are, of course, changing incentives—offering true value-based care contracts, for example—and then the whole creative destruction angle, wherein upstarts come in with far superior products and services, à la the whole Kodak case study or what happened to Sears and Kmart. Maybe this will happen in healthcare. Other ideas to transform the healthcare industry include employers harnessing the latent power that they have in some markets and then, of course, getting rid of middle people, for sure. Or we could go single payer, of course. That's another suggestion/solution. Today's conversation is a rather holistic look at all of this. I dig into this with David Muhlestein, who is chief research and innovation officer at Health Management Association (HMA). And when I say dig in, I mean dig in. David made some very intriguing points that I had not heard before, actually—and I've heard a lot in my time, so that's saying something. I'm gonna tick off a couple of them, but I don't do them justice. So, you'll need to listen to David explain them and give context. First off, what's the problem with healthcare being a $4 trillion industry in this country—I mean, almost 20% of GDP—and employing more people than any other industry in 47 of our 50 states? There are other big sectors in our economy, after all, that get lots of love. Why is big healthcare “bad” and these other sectors “good” in economic terms when we talk about employment? That's one thing I wanted to know. And David made a point that may be self-evident for some but is worth reiterating in all cases. The government pays for roughly half of healthcare, and from a consumer or just American standpoint, it kind of sucks. I mean, I don't see many Insta selfies of someone rocking their brand-new insurance premium. Dollars going to healthcare or health insurance are not going to consumer goods. And that matters economically as well as retail therapy. For all you econ geeks out there, this industry offers no marginal utility. Here's a second interesting point: Just changing incentives might not be enough. Organizations downstream and upstream need to be on board with the spirit and objective of the incentive change. If they are not, then it's game on for every CFO and their revenue cycle managers to finagle how to find the loophole that enables revenue maximization. Revenue maximization. Period. Revenue. The end. Which brings me to another interesting point: Boards of directors, CEOs, people with fiduciary responsibility … they need to know thyself and consider their actual customer. Spoiler alert: 99% of the time, that actual customer is not patients, no matter what is printed in big letters on the front door. No change can really happen unless those who serve in the upper echelons of these businesses get really real about where their bread is buttered. Organizations are built to serve their customer, after all. So, if a patient isn't identified as a customer, the organization at its very core is gonna have a lot of difficulty serving the patient. So, now what? If I want my organization to move forward in a way that is more patient-centric and less financially toxic, say, what to do? Here's thoughts after chatting with David Muhlestein. Four main steps: As I just said, you gotta get your current state unemotionally understood. For reals, who is the organization built to serve? So, first step is being introspective in the harsh light of day. Consider the timeline of your existential demise. Ha ha, this show is so uplifting. But unless organizations really think out 5 years, 10 years, 25 years and really internalize the existential threat, it's going to be hard to motivate change. I see this all the time. So do you. Inertia is real. Nobody does anything until they absolutely have to. Sidebar: But if you need an eventual demise to bring up at your next strategy meeting, I just saw a paper come out saying that by 2030, cost-related nonadherence could become a leading cause of death in the United States, surpassing diabetes, influenza, pneumonia, and kidney disease. This is as per a study by the nonprofit West Health Policy Center and Xcenda. Nonadherence … what does that mean? It means the patient is not doing their treatment. They are not going to the doctor or getting medical care or not taking their drugs. Meaning no one is making money off of all of those patients, especially when they're dead. This is where the rubber meets all of those excess profits everybody is reaping in the short term. I hope that was helpful for anybody trying to motivate change today.   Consider what legacy we want to leave behind. Do we all want to wait until we're forced to change to do so? Is this the healthcare system we want to leave behind to children and grandchildren? I mean, anybody who's got a loved one in the hospital with anything complex, fighting for their own patient records, on the phone for hours a day with insurance carriers while care is delayed with possibly devastating consequences, the family having to coordinate care and cross their fingers and pray they don't get a ridiculous bill for services that may or may not have been rendered and then use retirement savings to pay for them … if anyone is not looking to be a party to all of this, then let's think about our strategy moving forward and how it will change to meet the future we want to see. On to the evolve and change approaches: How exactly do you think about doing that? According to David Muhlestein, you can repair your current organization or remodel or rebuild. It sounds daunting, but as Dr. Eric Bricker said on our recent interview together (EP351) and as others have said as well, this is already happening in some regions across the country. There are pockets with real transformation. These changes are on the edges right now, but they're showing that this can and is possible.   You can learn more at healthmanagement.com.   David Muhlestein, PhD, JD, is chief research and innovation officer for Health Management Associates (HMA). He is responsible for the firm's self-directed research and supports strategic planning and innovation. David's research and expertise center on healthcare payment and delivery transformation, understanding healthcare markets, and evaluating how the broader healthcare system is changing. He is a self-identified data nerd and regularly speaks and writes about healthcare system evolution. David joined HMA via its acquisition of Leavitt Partners in 2021, where he was the chief strategy and chief research officer. Additionally, David is a visiting policy fellow at the Margolis Center for Health Policy at Duke University, adjunct assistant professor at The Ohio State University College of Public Health, and a visiting fellow at the Accountable Care Learning Collaborative. He previously served as adjunct assistant professor of The Dartmouth Institute (TDI) at the Geisel School of Medicine at Dartmouth College. David earned his PhD in health services management and policy, JD, MHA, and MS from The Ohio State University and a BA from Brigham Young University. 07:38 Is it an issue for the healthcare industry that it is one of the largest employers in the country? 08:42 “I think that we need to figure out what is an appropriate amount to spend on healthcare and get to that level.” 09:01 How do we not decrease the amount of healthcare we're receiving while paying less for that healthcare? 10:11 What are the two ways we can look at decreasing healthcare spend? 15:39 “I think that a regional approach may happen.” 16:56 “When somebody takes less, others are going to follow them.” 17:33 Who is really paying in our current healthcare system? 19:47 “Any sort of a model that you start with influences everything else that you do.” 20:09 What's the common challenge David Muhlestein sees in value-based care systems? 23:21 “There are countless things that you can do to improve the current system today.” 27:25 What are the three options for building up better healthcare? 28:19 David's advice for healthcare executives. 33:22 “To really lower the total cost of … healthcare, it's a 30-year process.” You can learn more at healthmanagement.com.   @DavidMuhlestein discusses #healthcaretransformation on our #healthcarepodcast. #healthcare #podcast #digitalhealth Is it an issue for the healthcare industry that it is one of the largest employers in the country? @DavidMuhlestein discusses #healthcaretransformation on our #healthcarepodcast. #healthcare #podcast #digitalhealth “I think that we need to figure out what is an appropriate amount to spend on healthcare and get to that level.” @DavidMuhlestein discusses #healthcaretransformation on our #healthcarepodcast. #healthcare #podcast #digitalhealth How do we not decrease the amount of healthcare we're receiving while paying less for that healthcare? @DavidMuhlestein discusses #healthcaretransformation on our #healthcarepodcast. #healthcare #podcast #digitalhealth What are the two ways we can look at decreasing healthcare spend? @DavidMuhlestein discusses #healthcaretransformation on our #healthcarepodcast. #healthcare #podcast #digitalhealth “I think that a regional approach may happen.” @DavidMuhlestein discusses #healthcaretransformation on our #healthcarepodcast. #healthcare #podcast #digitalhealth “When somebody takes less, others are going to follow them.” @DavidMuhlestein discusses #healthcaretransformation on our #healthcarepodcast. #healthcare #podcast #digitalhealth Who is really paying in our current healthcare system? @DavidMuhlestein discusses #healthcaretransformation on our #healthcarepodcast. #healthcare #podcast #digitalhealth “Any sort of a model that you start with influences everything else that you do.” @DavidMuhlestein discusses #healthcaretransformation on our #healthcarepodcast. #healthcare #podcast #digitalhealth What's the common challenge David Muhlestein sees in value-based care systems? @DavidMuhlestein discusses #healthcaretransformation on our #healthcarepodcast. #healthcare #podcast #digitalhealth “There are countless things that you can do to improve the current system today.” @DavidMuhlestein discusses #healthcaretransformation on our #healthcarepodcast. #healthcare #podcast #digitalhealth “To really lower the total cost of … healthcare, it's a 30-year process.” @DavidMuhlestein discusses #healthcaretransformation on our #healthcarepodcast. #healthcare #podcast #digitalhealth   Recent past interviews: Click a guest's name for their latest RHV episode! David Scheinker, Ali Ucar, Dr Carly Eckert, Jeb Dunkelberger (EP360), Dan O'Neill, Dr Wayne Jenkins, Liliana Petrova, Ge Bai, Nikhil Krishnan, Shawn Rhodes, Pramod John (EP353), Pramod John (EP352), Dr Eric Bricker, Katy Talento, Stacey Richter (INBW33), Stacey Richter (INBW32), Dr Steve Schutzer (Encore! EP294), Lisa Trumble, Jeb Dunkelberger, Dr Ian Tong, Mike Schneider, Peter Hayes, Paul Simms, Dr Steven Quimby, Dr David Carmouche (EP343), Christin Deacon, Gary Campbell, Kristin Begley  

Hi friends, this is Dr. Michael Williams and welcome back to another episode of the diversify in path podcast. This podcast explores how investing in diversity can lead to a high return of investment in pathology and laboratory medicine by learning from the knowledge and experiences of diverse voices within our field.My next guest is Dr. Laura TafeDr. Laura Tafe is an Associate Professor of Pathology and Laboratory Medicine at Dartmouth-Hitchcock Medical Center and the Geisel School of Medicine at Dartmouth where she is also an Assistant Director of the Laboratory for Clinical Genomics and Advanced Technology (CGAT).  Dr. Tafe attended Wayne State University School of Medicine in Detroit, MI and completed AP/CP residency at Dartmouth-Hitchcock Medical Center followed by fellowship training in oncologic surgical pathology and molecular genetic pathology at Memorial Sloan Kettering Cancer Center.  Dr. Tafe's academic interests focus on thoracic and gynecologic neoplasms and molecular diagnostics.  She is currently a member of CAP's Molecular Oncology Committee, was most recently the Chair of the Program Committee for the Association for Molecular Pathology (AMP) and now is the President-Elect of AMP. Twitter:  Laura J. Tafe, MD (@LJTafeMD) / Twitter

Dr. Jay Lemery, Professor of Emergency Medicine at The University of Colorado School of Medicine, joins me today to discuss the relationship between climate change and human health, the growing field of climate medicine, as well as the advocacy required to affect realistic, positive change for our planet and ourselves. Bio: Dr. Lemery is an Associate Professor of Emergency Medicine at the University of Colorado School of Medicine and is Chief of the Section of Wilderness and Environmental Medicine. He is a Past-President of the Wilderness Medical Society and has provided medical direction to National Science Foundation subcontractors operating at both poles, most recently serving as the EMS Medical Director for the United States Antarctic Program. Dr. Lemery has an academic expertise in austere and remote medical care as well as the effects of climate change on human health. He serves as a consultant for the Climate and Health Program at the Centers for Disease Control and Prevention and sits on the National Academy of Medicine's (IOM) Roundtable on Environmental Health Sciences, Research, and Medicine. He is a Fellow of the American College of Emergency Physicians was a term member of the Council on Foreign Relations. He is the co-editor of Global Climate Change and Human Heath: From Science to Practice (2015) and co-author of Enviromedics (2017). He serves as an advisor to the organization Climate for Health (ecoAmerica) and the George Mason University Center for Climate Change Communication. From 2005-2012, he was the Director of Cornell Wilderness Medicine and a member of the Global Health Steering Committee at the Weill Cornell Medical College. Dr. Lemery was an Echols Scholar at the University of Virginia and received his MD from the Geisel School of Medicine at Dartmouth. From 2003-04 he was chief resident in Emergency Medicine at NYU & Bellevue Hospitals. In 2017, Dr. Lemery became the Director for the Living Closer Foundation physician GME Fellowship in Climate and Health Science Policy– the first of its kind in the nation. Website - https://www.coloradowm.org/blog/teachers/jay-lemery/ Book - https://www.amazon.de/Enviromedics-Impact-Climate-Change-Health/dp/144224318X Artwork by Phillip Thor - https://linktr.ee/Philipthor_art To watch the visuals with the trailer go to https://www.podcasttheway.com/trailers/ The Way Podcast - www.PodcastTheWay.com - Follow at Twitter / Instagram - @podcasttheway (Subscribe and Follow on streaming platforms and social media!) As always thank you Don Grant for the Intro and Outro. Check out his podcast - https://threeinterestingthings.captivate.fm Intro guitar copied from Aiden Ayers at https://www.youtube.com/watch?v=7UiB9FMOP5s *The views demonstrated in this show are strictly those of The Way Podcast/Radio Show*

Episode 22: Richard Peck is a certified financial planner, a chartered advisor in philanthropy, and a chartered financial consultant. Prior to the Charitable Foundation, Richard served Dartmouth Hitchcock Health, the Geisel School of Medicine, and Dartmouth College in their philanthropic work. He is a volunteer member of the marketing and development committee of the Grafton County Senior Citizens Council in Lebanon, NH. He also serves on the NH Race and Equity All Workgroup and the Civic Engagement subgroup in Concord, NH. And, he is a member of the board of directors of the International Association of Advisors in Philanthropy and serves on its webinar and marketing committees as well. For fun, in non-COVID times, Richard likes to perform improvisational comedy on stage with his troupe, which has been playing to groups large and small for over 25 years. Links:NH Charitable FoundationPicture Your Legacy CardsYour Next Adventure What next?What are your questions about volunteering as a retiree? Share your questions with us at info@seniorityauthority.org or find us on your favorite social media platform. Stay connected:Cathleen ToomeyLinkedin:Cathleen ToomeyWebsite:Seniority AuthorityFacebook:Seniority AuthorityInstagram:seniorityauthoritySubscribe to our podcast + download each episode onStitcher,Apple Podcasts,Google Podcasts andSpotify.

Episode 20: Dr. John Randolph is a board-certified clinical neuropsychologist, brain health coach and consultant, and member of the Adjunct Faculty at the Geisel School of Medicine at Dartmouth College. He earned his PhD in Clinical Psychology, with an emphasis in Neuropsychology at Washington State University, and completed clinical and research fellowships in Neuropsychology and Neuroimaging at the Geisel School of Medicine at Dartmouth. He's Past President of the New Hampshire Psychological Association, a National Academy of Neuropsychology (NAN) Fellow, and recent Program Chair for a national conference focused on the science of brain health. He's also the author of the recently released general audience book, The Brain Health Club: Using the Power of Neuroscience to Improve Your Life. He works with individuals, groups, and organizations interested in developing better strategies to enhance brain health. Links:The Brain Health Book What's next?What day-to-day activities are you engaging in to improve your brain health? Share your stories with us at info@seniorityauthority.org or find us on your favorite social media platform. Stay connected:Dr. John RandolphWebsite: www.randolphnp.comCathleen ToomeyLinkedin:Cathleen ToomeyWebsite:Seniority AuthorityFacebook:Seniority AuthorityInstagram:seniorityauthoritySubscribe to our podcast + download each episode onStitcher,Apple Podcasts,Google Podcasts andSpotify.

Margie is Research Professor in the Department of Nursing and Executive Director and Founder of the Institute for Excellence in Health and Social Systems (IEHSS), in the College of Health and Human Services at the University of New Hampshire. She is a national and international leader of designing and implementing improvement strategies targeting the place where patients, families and care teams meet-the clinical microsystem. Dr. Godfrey began her work in clinical microsystems over 25 years ago and, in 2009, founded The Dartmouth Institute Microsystem Academy (TDIMA) at The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine with Dartmouth colleagues, to develop new knowledge and disseminate findings. She was Co-Director of TDIMA with Dr. Tina Foster for 11 years and a Lecturer for nearly 20 years at The Dartmouth Institute for Health Policy and Clinical Practice.   Margie's primary interest is engaging inter-professional health care professionals in learning about and improving local health care delivery systems with a focus on patients, professionals, processes and outcomes. Margie is co-author of the best selling textbooks, Quality by Design (2007), Quality by Design, 2nd Edition (in press) and Value By Design (2011), and the lead author and architect of the "Clinical Microsystems: A Path to Healthcare Excellence" series. Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3 (https://www.surveymonkey.com/r/3DXCFW3) CME credit is available for up to 3 years after the stated release date Contact CEOD@bmhcc.org if you have any questions about claiming credit.

Episode SummaryThroughout Dr. Rowland Hazard's career, listening and human connection have been at the core of his success in both medicine and business. Through asking simple questions such as “who are you?” and “where are you from?” Rowley has been able to help people through the toughest period of their lives. Syd and Rowley discuss Rowley's journey from dishwasher to world-renowned MD and back pain specialist. Syd Finkelstein Syd Finkelstein is the Steven Roth Professor of Management at the Tuck School of Business at Dartmouth College. He holds a Master's degree from the London School of Economics and a Ph.D. from Columbia University. Professor Finkelstein has published 25 books and 90 articles, including the bestsellers Why Smart Executives Fail and Superbosses: How Exceptional Leaders Master the Flow of Talent, which LinkedIn Chairman Reid Hoffman calls the “leadership guide for the Networked Age.” He is also a Fellow of the Academy of Management, a consultant and speaker to leading companies around the world, and a top 25 on the Global Thinkers 50 list of top management gurus. Professor Finkelstein's research and consulting work often relies on in-depth and personal interviews with hundreds of people, an experience that led him to create and host his own podcast, The Sydcast, to uncover and share the stories of all sorts of fascinating people in business, sports, entertainment, politics, academia, and everyday life. Rowland G. HazardRowland G. Hazard, MD recently retired from an over 30-year career devoted to people disabled by chronic back pain. Currently Emeritus Professor of Orthopaedics at the Geisel School of Medicine at Dartmouth, he is a physician, internationally respected scholar and researcher, widely published author, teacher, inventor, entrepreneur, athlete and jazz musician. As a clinician and director of Functional Restoration Programs (FRPs) at the University of Vermont (1986-2000) and at the Dartmouth-Hitchcock Medical Center (2002-2018), Dr. Hazard cared for several thousand patients with back pain and lead FRP teams of physicians, psychologists, physical and occupational therapists, and trainers. A board-certified internist, he is a Fellow in the American College of Physicians. He has published over 50 journal articles and book chapters and delivered scores of related academic lectures and media appearances in the US, Europe and Australia. He has served as reviewer and technical expert for the US Agency for Healthcare Research and Quality and as an editorial board member of Spine and The Back Letter. He has twice represented the US at the International Society for the Study of the Lumbar Spine. His new book, Talking Back: How to Overcome Chronic Back Pain and Rebuild Your Life, was published by Rowman & Littlefield in May, 2021.Insights from this episode:How to effectively communicate with your doctor and peers about your goals and expectationsBenefits of following your skills and finding your passion within those skillsThe differences between pain and disability stemming from pain and fear of reinjuryAdvantages of manipulation and functional restoration for back pain and treating disabilityThe power of listening and its ability to propel you into success in a variety of different fieldsAdvice on how to treat and manage chronic, acute back painQuotes from the show:“I learned in a way that was completely different from the book learning I was accustomed to, and I loved it.” – Rowland G. Hazard [11:55] Episode #97“I just think true reform of the national healthcare system should involve education, research, and practice. Not just, you know, with your taxes, you're going to pay for your gall bladder operation. It's more complicated than that. ” – Rowland G. Hazard [23:01] Episode #97“I was hit over the head by how ignorant I was about how to take care of people who had back pain. So for almost a year, I dedicated Thursday nights. I stayed up every Thursday night, reading everything I could get my hands on about back pain.” – Rowland G. Hazard [24:00] Episode #97“There's a huge variety of treatments out there for back pain. There are many belief systems underneath those that pass as science, but the science is actually pretty thin.” – Rowland G. Hazard [27:06] Episode #97“If I go back to doing all the things I did before, there is a fear of getting much worse. The pain itself is not terrible, it's manageable. Just you sharing that actually is good to know. It at least helps me process it in my head and recognize what choice is happening implicitly” Syd Finkelstein– [37:20] Episode #97“You gotta have passion, and you have to work hard. You can be fearless, but if you can't listen, you can drive really hard down the wrong road quickly.” – Rowland G. Hazard [46:25] Episode #97“In my own practice, I rarely talked to people about opioids, even though I was seeing ‘the worst of the worst of the chronic pain patients'.” – Rowland G. Hazard [59:48] Episode #97“90% of people who have an acute episode of back pain get better, almost no matter what you do.” – Rowland G. Hazard [62:29] Episode #97Stay Connected: Syd FinkelsteinWebsite: http://thesydcast.comLinkedIn: Sydney FinkelsteinTwitter: @sydfinkelsteinFacebook: The SydcastInstagram: The SydcastRowland G. Hazard New book: Talking Back: How to Overcome Chronic Back Pain and Rebuild Your LifeLInkedIn: https://www.linkedin.com/in/rowland-hazard-8a8a2174/ Subscribe to our podcast + download each episode on Stitcher, iTunes, and Spotify. This episode was produced and managed by Podcast Laundry (www.podcastlaundry.com)